Intra-Cellular Therapies Inc. (ITCI) NASDAQ
$69.72 2.39 (3.55%)
Market Cap: $6.75B
As of 03/27/24 04:00 PM EDT. Market closed.
Intra-Cellular Therapies Inc. (ITCI)
NASDAQ
$69.72
2.39 (3.55%)
Market Cap: $6.75B
As of 03/27/24 04:00 PM EDT. Market closed.
Add to Portfolio
intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united ... read more
intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states. read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO Compensation (Base)
$722,800
CEO Compensation (Total)
$4.48M
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Sharon Mates
CEO Compensation (Base)
$722,800
CEO Compensation (Total)
$4.48M
Address
430 E 29th St, New York, New York, 10016-8367.
PRICE CHART FOR INTRA-CELLULAR THERAPIES INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$67.99
Previous Close
$67.33
Days Range
$67.54 - $69.75
52 week range
$45.50 - $76.11
Volume
428,676
Avg. Volume (30 days)
644,540
Market Cap
$6.75B
Dividend Yield
-
P/E
-
Shares Outstanding
96,807,191
Open
$67.99
Previous Close
$67.33
Days Range
$67.54 - $69.75
52 week range
$45.50 - $76.11
Volume
428,676
Avg. Volume (30 days)
644,540
Market Cap
$6.75B
Dividend Yield
-
P/E
-
Shares Outstanding
96,807,191
FINANCIAL STATEMENTS FOR INTRA-CELLULAR THERAPIES INC
LOADING...
INSIDER TRANSACTIONS FOR INTRA-CELLULAR THERAPIES INC
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
RIGGS RORY B | Director | Mar 20, 2024 | Option Exercise | $18.56 | 20,000 | 371,200 | 99,235 | Mar 22, 2024, 04:12 PM |
Mates Sharon | Chairman, President & CEO | Mar 07, 2024 | Sale | $66.50 | 40,712 | 2,707,277 | 1,059,063 | Mar 11, 2024, 08:33 PM |
Mates Sharon | Chairman, President & CEO | Mar 11, 2024 | Sale | $65.21 | 20,565 | 1,341,123 | 1,056,333 | Mar 11, 2024, 08:33 PM |
Hineline Lawrence J. | SVP of Finance, CFO | Mar 10, 2024 | Option Exercise | $56.73 | 4,539 | 257,497 | 4,539 | Mar 11, 2024, 08:33 PM |
Hineline Lawrence J. | SVP of Finance, CFO | Mar 11, 2024 | Sale | $65.96 | 10,121 | 667,587 | 1,129 | Mar 11, 2024, 08:33 PM |
Hineline Lawrence J. | SVP of Finance, CFO | Mar 07, 2024 | Sale | $66.60 | 13,132 | 874,560 | 6,618 | Mar 11, 2024, 08:33 PM |
Halstead Michael | EVP and General Counsel | Mar 11, 2024 | Sale | $65.97 | 7,345 | 484,537 | 1,238 | Mar 11, 2024, 08:32 PM |
Halstead Michael | EVP and General Counsel | Mar 07, 2024 | Sale | $66.15 | 13,132 | 868,698 | 220 | Mar 11, 2024, 08:32 PM |
Neumann Mark | EVP, Chief Commercial Officer | Mar 11, 2024 | Sale | $65.61 | 7,345 | 481,931 | 32,742 | Mar 11, 2024, 08:31 PM |
Neumann Mark | EVP, Chief Commercial Officer | Mar 07, 2024 | Sale | $66.57 | 13,132 | 874,179 | 34,196 | Mar 11, 2024, 08:31 PM |
Durgam Suresh K. | EVP, Chief Medical Officer | Mar 11, 2024 | Sale | $65.59 | 3,712 | 243,482 | 21,336 | Mar 11, 2024, 08:31 PM |
Durgam Suresh K. | EVP, Chief Medical Officer | Mar 07, 2024 | Sale | $66.56 | 6,450 | 429,308 | 18,892 | Mar 11, 2024, 08:31 PM |
VAN NOSTRAND ROBERT L | Director | Feb 27, 2024 | Option Exercise | $18.56 | 20,000 | 371,200 | 29,611 | Feb 28, 2024, 07:41 PM |
VAN NOSTRAND ROBERT L | Director | Feb 27, 2024 | Sale | $72.93 | 20,000 | 1,458,650 | 19,960 | Feb 28, 2024, 07:41 PM |
Halstead Michael | EVP and General Counsel | Feb 26, 2024 | Sale | $69.53 | 7,907 | 549,784 | 7,607 | Feb 27, 2024, 08:00 PM |
Hineline Lawrence J. | SVP of Finance, CFO | Feb 26, 2024 | Option Exercise | $36.89 | 5,882 | 216,987 | 5,882 | Feb 27, 2024, 08:00 PM |
Hineline Lawrence J. | SVP of Finance, CFO | Feb 26, 2024 | Sale | $69.43 | 13,337 | 925,961 | 7,155 | Feb 27, 2024, 08:00 PM |
Mates Sharon | Chairman, President & CEO | Feb 26, 2024 | Sale | $69.79 | 22,590 | 1,576,464 | 1,072,299 | Feb 27, 2024, 07:59 PM |
Durgam Suresh K. | EVP, Chief Medical Officer | Feb 26, 2024 | Sale | $70.17 | 4,112 | 288,534 | 12,200 | Feb 27, 2024, 07:58 PM |
Neumann Mark | EVP, Chief Commercial Officer | Feb 26, 2024 | Sale | $70.13 | 7,907 | 554,491 | 37,407 | Feb 27, 2024, 07:58 PM |
MARCUS JOEL S | Director | Feb 26, 2024 | Option Exercise | $48.93 | 36,757 | 1,798,678 | 65,990 | Feb 27, 2024, 07:57 PM |
MARCUS JOEL S | Director | Feb 26, 2024 | Sale | $68.68 | 26,328 | 1,808,253 | 57,619 | Feb 27, 2024, 07:57 PM |
Halstead Michael | EVP and General Counsel | Feb 02, 2024 | Sale | $66.42 | 11,860 | 787,719 | 714 | Feb 05, 2024, 06:13 PM |
Mates Sharon | Chairman, President & CEO | Feb 02, 2024 | Sale | $67.07 | 33,885 | 2,272,693 | 1,067,759 | Feb 05, 2024, 06:10 PM |
Neumann Mark | EVP, Chief Commercial Officer | Feb 02, 2024 | Sale | $67.15 | 11,860 | 796,367 | 36,604 | Feb 05, 2024, 06:07 PM |
Hineline Lawrence J. | SVP of Finance, CFO | Feb 02, 2024 | Sale | $66.62 | 11,183 | 745,037 | 185 | Feb 05, 2024, 06:05 PM |
Durgam Suresh K. | EVP, Chief Medical Officer | Feb 02, 2024 | Sale | $67.19 | 6,167 | 414,355 | 9,540 | Feb 05, 2024, 06:02 PM |
Mates Sharon | Chairman, President & CEO | Jan 16, 2024 | Option Exercise | $16.86 | 75,361 | 1,270,587 | 1,125,670 | Jan 18, 2024, 07:47 PM |
Mates Sharon | Chairman, President & CEO | Jan 18, 2024 | Option Exercise | $16.86 | 67,917 | 1,145,081 | 1,118,226 | Jan 18, 2024, 07:47 PM |
Mates Sharon | Chairman, President & CEO | Jan 17, 2024 | Option Exercise | $16.86 | 48,084 | 810,696 | 1,098,393 | Jan 18, 2024, 07:47 PM |
Mates Sharon | Chairman, President & CEO | Jan 16, 2024 | Sale | $67.25 | 75,361 | 5,067,982 | 1,122,170 | Jan 18, 2024, 07:47 PM |
Mates Sharon | Chairman, President & CEO | Jan 18, 2024 | Sale | $65.19 | 67,917 | 4,427,849 | 1,050,629 | Jan 18, 2024, 07:47 PM |
Mates Sharon | Chairman, President & CEO | Jan 17, 2024 | Sale | $66.24 | 48,084 | 3,185,062 | 1,067,760 | Jan 18, 2024, 07:47 PM |
Halstead Michael | EVP and General Counsel | Jan 11, 2024 | Option Exercise | $13.60 | 50,000 | 680,051 | 50,000 | Jan 12, 2024, 06:02 PM |
Halstead Michael | EVP and General Counsel | Jan 11, 2024 | Sale | $66.83 | 50,000 | 3,341,698 | 31,846 | Jan 12, 2024, 06:02 PM |
Durgam Suresh K. | EVP, Chief Medical Officer | Jan 02, 2024 | Option Exercise | $19.87 | 62,282 | 1,237,543 | 62,282 | Jan 04, 2024, 07:54 PM |
Durgam Suresh K. | EVP, Chief Medical Officer | Jan 02, 2024 | Sale | $70.60 | 62,282 | 4,397,113 | 24,855 | Jan 04, 2024, 07:54 PM |
RIGGS RORY B | Director | Dec 31, 2023 | Option Exercise | $71.62 | 251 | 17,977 | 79,235 | Jan 03, 2024, 06:46 PM |
VAN NOSTRAND ROBERT L | Director | Dec 31, 2023 | Option Exercise | $71.62 | 76 | 5,443 | 9,611 | Jan 03, 2024, 06:43 PM |
Durgam Suresh K. | EVP, Chief Medical Officer | Dec 13, 2023 | Sale | $65.00 | 21,262 | 1,382,030 | 0 | Dec 15, 2023, 05:01 PM |
Halstead Michael | EVP and General Counsel | Nov 13, 2023 | Option Exercise | $13.56 | 50,000 | 678,049 | 50,000 | Nov 14, 2023, 05:33 PM |
Halstead Michael | EVP and General Counsel | Nov 13, 2023 | Sale | $53.90 | 50,000 | 2,694,783 | 41,067 | Nov 14, 2023, 05:33 PM |
Neumann Mark | EVP, Chief Commercial Officer | Nov 06, 2023 | Option Exercise | $23.94 | 26,754 | 640,491 | 72,093 | Nov 08, 2023, 05:31 PM |
Neumann Mark | EVP, Chief Commercial Officer | Nov 06, 2023 | Sale | $55.63 | 42,393 | 2,358,152 | 45,339 | Nov 08, 2023, 05:31 PM |
VAN NOSTRAND ROBERT L | Director | Sep 30, 2023 | Option Exercise | $52.09 | 105 | 5,469 | 9,535 | Oct 02, 2023, 05:30 PM |
RIGGS RORY B | Director | Sep 30, 2023 | Option Exercise | $52.09 | 345 | 17,971 | 78,984 | Oct 02, 2023, 05:29 PM |
Mates Sharon | Chairman, President & CEO | Sep 19, 2023 | Sale | $54.17 | 44,413 | 2,405,852 | 1,050,309 | Sep 19, 2023, 08:40 PM |
Mates Sharon | Chairman, President & CEO | Sep 18, 2023 | Sale | $53.76 | 55,587 | 2,988,213 | 1,122,841 | Sep 19, 2023, 08:40 PM |
Neumann Mark | EVP, Chief Commercial Officer | Aug 07, 2023 | Option Exercise | $18.59 | 55,300 | 1,028,027 | 100,639 | Aug 09, 2023, 06:05 PM |
Neumann Mark | EVP, Chief Commercial Officer | Aug 07, 2023 | Sale | $58.79 | 55,300 | 3,251,087 | 45,339 | Aug 09, 2023, 06:05 PM |
Durgam Suresh K. | EVP, Chief Medical Officer | Jul 17, 2023 | Sale | $65.00 | 1,842 | 119,730 | 21,262 | Jul 20, 2023, 05:47 PM |
VAN NOSTRAND ROBERT L | Director | Jun 30, 2023 | Option Exercise | $63.32 | 85 | 5,382 | 9,430 | Jul 05, 2023, 04:29 PM |
Hineline Lawrence J. | SVP of Finance CFO | Jun 14, 2023 | Option Exercise | $42.30 | 81,854 | 3,462,317 | 81,854 | Jun 16, 2023, 05:05 PM |
Hineline Lawrence J. | SVP of Finance CFO | Jun 14, 2023 | Sale | $63.97 | 81,854 | 5,236,329 | 47,627 | Jun 16, 2023, 05:05 PM |
VAN NOSTRAND ROBERT L | Director | Apr 17, 2023 | Option Exercise | $13.05 | 10,000 | 130,500 | 19,345 | Apr 19, 2023, 06:00 PM |
VAN NOSTRAND ROBERT L | Director | Apr 17, 2023 | Sale | $63.00 | 10,000 | 630,000 | 9,345 | Apr 19, 2023, 06:00 PM |
RIGGS RORY B | Director | Mar 31, 2023 | Option Exercise | $54.15 | 313 | 16,949 | 78,360 | Apr 04, 2023, 05:01 PM |
Neumann Mark | EVP, Chief Commercial Officer | Mar 28, 2023 | Sale | $54.31 | 15,604 | 847,380 | 55,522 | Mar 30, 2023, 05:08 PM |
Durgam Suresh K. | EVP, Chief Medical Officer | Mar 13, 2023 | Sale | $45.04 | 7,344 | 330,794 | 23,450 | Mar 13, 2023, 07:36 PM |
Neumann Mark | EVP, Chief Commercial Officer | Mar 13, 2023 | Sale | $44.98 | 3,758 | 169,042 | 61,366 | Mar 13, 2023, 07:35 PM |
Neumann Mark | EVP, Chief Commercial Officer | Mar 10, 2023 | Sale | $43.34 | 8,550 | 370,557 | 59,157 | Mar 13, 2023, 07:35 PM |
Halstead Michael | EVP and General Counsel | Mar 13, 2023 | Sale | $44.94 | 7,344 | 330,007 | 476 | Mar 13, 2023, 07:34 PM |
Halstead Michael | EVP and General Counsel | Mar 10, 2023 | Sale | $43.10 | 16,708 | 720,086 | 2,500 | Mar 13, 2023, 07:34 PM |
Hineline Lawrence J. | SVP of Finance CFO | Mar 13, 2023 | Sale | $44.93 | 5,582 | 250,808 | 258 | Mar 13, 2023, 07:32 PM |
Hineline Lawrence J. | SVP of Finance CFO | Mar 10, 2023 | Sale | $43.06 | 15,663 | 674,417 | 2,700 | Mar 13, 2023, 07:32 PM |
Mates Sharon | Chairman, President & CEO | Mar 13, 2023 | Option Exercise | $3.26 | 20,000 | 65,200 | 1,150,309 | Mar 13, 2023, 07:31 PM |
Mates Sharon | Chairman, President & CEO | Mar 13, 2023 | Sale | $44.99 | 20,565 | 925,275 | 1,131,721 | Mar 13, 2023, 07:31 PM |
Mates Sharon | Chairman, President & CEO | Mar 10, 2023 | Sale | $43.15 | 41,770 | 1,802,566 | 1,137,114 | Mar 13, 2023, 07:31 PM |
Neumann Mark | EVP, Chief Commercial Officer | Mar 01, 2023 | Sale | $50.01 | 7,241 | 362,122 | 49,199 | Mar 03, 2023, 07:03 PM |
Neumann Mark | EVP, Chief Commercial Officer | Feb 24, 2023 | Sale | $47.12 | 4,046 | 190,648 | 56,440 | Feb 27, 2023, 08:03 PM |
Durgam Suresh K. | SVP, Chief Medical Officer | Feb 24, 2023 | Sale | $47.14 | 7,906 | 372,689 | 23,104 | Feb 27, 2023, 08:02 PM |
Halstead Michael | EVP and General Counsel | Feb 24, 2023 | Sale | $47.03 | 7,906 | 371,819 | 0 | Feb 27, 2023, 08:01 PM |
Hineline Lawrence J. | SVP of Finance CFO | Feb 24, 2023 | Sale | $47.03 | 7,455 | 350,609 | 0 | Feb 27, 2023, 08:00 PM |
Mates Sharon | Chairman, President & CEO | Feb 24, 2023 | Option Exercise | $3.26 | 30,000 | 97,800 | 1,130,309 | Feb 27, 2023, 07:59 PM |
Mates Sharon | Chairman, President & CEO | Feb 24, 2023 | Sale | $47.03 | 22,590 | 1,062,408 | 1,100,309 | Feb 27, 2023, 07:59 PM |
Neumann Mark | EVP, Chief Commercial Officer | Feb 21, 2023 | Sale | $47.01 | 3,898 | 183,246 | 53,338 | Feb 22, 2023, 08:05 PM |
Durgam Suresh K. | SVP, Chief Medical Officer | Feb 21, 2023 | Sale | $46.84 | 8,354 | 391,304 | 24,785 | Feb 22, 2023, 08:04 PM |
Halstead Michael | EVP and General Counsel | Feb 21, 2023 | Sale | $46.84 | 11,139 | 521,699 | 1,843 | Feb 22, 2023, 08:03 PM |
Hineline Lawrence J. | SVP of Finance CFO | Feb 17, 2023 | Option Exercise | $12.73 | 53,968 | 687,013 | 53,968 | Feb 22, 2023, 08:02 PM |
Hineline Lawrence J. | SVP of Finance CFO | Feb 21, 2023 | Sale | $46.82 | 10,443 | 488,891 | 1,794 | Feb 22, 2023, 08:02 PM |
Hineline Lawrence J. | SVP of Finance CFO | Feb 17, 2023 | Sale | $49.83 | 53,968 | 2,689,464 | 1,689 | Feb 22, 2023, 08:02 PM |
Mates Sharon | Chairman, President & CEO | Feb 21, 2023 | Sale | $46.83 | 27,848 | 1,304,000 | 1,105,262 | Feb 22, 2023, 08:01 PM |
VAN NOSTRAND ROBERT L | Director | Dec 30, 2022 | Option Exercise | $52.92 | 97 | 5,133 | 9,250 | Jan 03, 2023, 04:19 PM |
RIGGS RORY B | Director | Dec 30, 2022 | Option Exercise | $52.92 | 321 | 16,987 | 78,047 | Jan 03, 2023, 04:18 PM |
MARCUS JOEL S | Director | Dec 19, 2022 | Sale | $50.82 | 5,000 | 254,100 | 29,233 | Dec 21, 2022, 04:06 PM |
Mates Sharon | Chairman, President & CEO | Dec 13, 2022 | Sale | $55.00 | 33,083 | 1,819,565 | 1,100,309 | Dec 15, 2022, 07:01 PM |
Halstead Michael | EVP and General Counsel | Dec 01, 2022 | Option Exercise | $15.47 | 50,000 | 773,500 | 50,000 | Dec 02, 2022, 07:14 PM |
Halstead Michael | EVP and General Counsel | Dec 01, 2022 | Sale | $53.73 | 50,000 | 2,686,514 | 22,796 | Dec 02, 2022, 07:14 PM |
MARCUS JOEL S | Director | Nov 07, 2022 | Sale | $52.30 | 10,000 | 523,023 | 39,233 | Nov 08, 2022, 04:12 PM |
VAN NOSTRAND ROBERT L | Director | Sep 30, 2022 | Option Exercise | $46.53 | 110 | 5,118 | 9,153 | Oct 05, 2022, 04:04 PM |
RIGGS RORY B | Director | Sep 30, 2022 | Option Exercise | $46.53 | 365 | 16,983 | 77,726 | Oct 04, 2022, 04:11 PM |
Hineline Lawrence J. | SVP of Finance CFO | Sep 21, 2022 | Option Exercise | $15.47 | 65,164 | 1,008,087 | 65,164 | Sep 23, 2022, 09:01 PM |
Hineline Lawrence J. | SVP of Finance CFO | Sep 21, 2022 | Sale | $45.63 | 65,164 | 2,973,406 | 33,303 | Sep 23, 2022, 09:01 PM |
VAN NOSTRAND ROBERT L | Director | Aug 11, 2022 | Option Exercise | $12.65 | 30,000 | 379,500 | 39,043 | Aug 12, 2022, 06:09 PM |
VAN NOSTRAND ROBERT L | Director | Aug 11, 2022 | Sale | $57.13 | 30,000 | 1,713,975 | 10,543 | Aug 12, 2022, 06:09 PM |
MARCUS JOEL S | Director | Aug 11, 2022 | Sale | $59.22 | 10,000 | 592,200 | 44,233 | Aug 12, 2022, 06:05 PM |
RIGGS RORY B | Director | Jun 30, 2022 | Option Exercise | $57.08 | 289 | 16,496 | 77,361 | Jul 05, 2022, 04:06 PM |
MARCUS JOEL S | Director | May 12, 2022 | Sale | $55.00 | 10,000 | 550,000 | 54,233 | May 13, 2022, 05:24 PM |
Neumann Mark | EVP, Chief Commercial Officer | Apr 08, 2022 | Option Exercise | $12.73 | 86,348 | 1,099,210 | 131,687 | Apr 08, 2022, 06:56 PM |
Neumann Mark | EVP, Chief Commercial Officer | Apr 08, 2022 | Sale | $64.37 | 86,348 | 5,558,051 | 114,211 | Apr 08, 2022, 06:56 PM |
VAN NOSTRAND ROBERT L | Director | Mar 31, 2022 | Option Exercise | $61.19 | 126 | 7,710 | 8,935 | Apr 04, 2022, 04:11 PM |
RIGGS RORY B | Director | Mar 31, 2022 | Option Exercise | $61.19 | 257 | 15,726 | 77,072 | Apr 04, 2022, 04:08 PM |
RIGGS RORY B | Director | Mar 18, 2022 | Sale | $61.18 | 20,637 | 1,262,505 | 15,736 | Mar 18, 2022, 08:12 PM |
RIGGS RORY B | Director | Mar 17, 2022 | Sale | $60.33 | 141,499 | 8,536,646 | 135,549 | Mar 18, 2022, 08:12 PM |
RIGGS RORY B | Director | Mar 16, 2022 | Sale | $59.27 | 64,534 | 3,824,827 | 205,984 | Mar 18, 2022, 08:12 PM |
Mates Sharon | Chairman, President & CEO | Mar 09, 2022 | Option Exercise | $2.84 | 38,925 | 110,547 | 1,133,392 | Mar 10, 2022, 04:13 PM |
MARCUS JOEL S | Director | Mar 08, 2022 | Sale | $52.68 | 15,000 | 790,150 | 38,980 | Mar 09, 2022, 09:49 PM |
MARCUS JOEL S | Director | Mar 07, 2022 | Sale | $54.52 | 5,000 | 272,600 | 43,980 | Mar 09, 2022, 09:49 PM |
Durgam Suresh K. | Chief Medical Officer | Mar 02, 2022 | Sale | $56.98 | 4,177 | 238,005 | 26,964 | Mar 04, 2022, 06:05 PM |
Durgam Suresh K. | Chief Medical Officer | Mar 04, 2022 | Sale | $55.52 | 3,860 | 214,307 | 23,104 | Mar 04, 2022, 06:05 PM |
Durgam Suresh K. | Chief Medical Officer | Feb 24, 2022 | Sale | $52.27 | 4,046 | 211,468 | 33,984 | Feb 25, 2022, 07:09 PM |
Neumann Mark | EVP, Chief Commercial Officer | Feb 24, 2022 | Sale | $52.21 | 7,906 | 412,810 | 50,585 | Feb 25, 2022, 07:08 PM |
Halstead Michael | EVP and General Counsel | Feb 24, 2022 | Sale | $51.98 | 7,906 | 410,933 | 4,188 | Feb 25, 2022, 07:06 PM |
Hineline Lawrence J. | SVP of Finance CFO | Feb 24, 2022 | Sale | $51.97 | 7,454 | 387,349 | 4,083 | Feb 25, 2022, 07:04 PM |
Mates Sharon | Chairman, President & CEO | Feb 24, 2022 | Sale | $51.98 | 22,589 | 1,174,074 | 1,105,807 | Feb 25, 2022, 07:01 PM |
Durgam Suresh K. | Chief Medical Officer | Feb 22, 2022 | Sale | $55.29 | 4,177 | 230,958 | 28,638 | Feb 23, 2022, 07:08 PM |
Neumann Mark | EVP, Chief Commercial Officer | Feb 22, 2022 | Sale | $55.29 | 11,139 | 615,827 | 49,946 | Feb 23, 2022, 07:07 PM |
Halstead Michael | EVP and General Counsel | Feb 22, 2022 | Sale | $55.40 | 11,139 | 617,100 | 4,550 | Feb 23, 2022, 07:05 PM |
Hineline Lawrence J. | SVP of Finance CFO | Feb 22, 2022 | Sale | $55.40 | 10,443 | 578,506 | 4,627 | Feb 23, 2022, 07:02 PM |
Mates Sharon | Chairman, President & CEO | Feb 22, 2022 | Sale | $55.39 | 27,847 | 1,542,413 | 1,107,134 | Feb 23, 2022, 07:00 PM |
Durgam Suresh K. | Chief Medical Officer | Jan 18, 2022 | Sale | $42.03 | 6,223 | 261,553 | 23,104 | Jan 20, 2022, 04:07 PM |
Durgam Suresh K. | Chief Medical Officer | Jan 10, 2022 | Sale | $40.76 | 6,870 | 280,020 | 34,677 | Jan 11, 2022, 08:08 PM |
Neumann Mark | EVP, Chief Commercial Officer | Jan 10, 2022 | Sale | $40.78 | 20,948 | 854,255 | 63,526 | Jan 11, 2022, 08:06 PM |
Halstead Michael | EVP and General Counsel | Jan 10, 2022 | Sale | $40.77 | 19,639 | 800,774 | 17,135 | Jan 11, 2022, 08:04 PM |
Hineline Lawrence J. | SVP of Finance CFO | Jan 10, 2022 | Sale | $40.76 | 19,639 | 800,420 | 16,534 | Jan 11, 2022, 08:02 PM |
Mates Sharon | Chairman, President & CEO | Jan 10, 2022 | Sale | $40.78 | 41,896 | 1,708,429 | 1,130,559 | Jan 11, 2022, 08:00 PM |
VAN NOSTRAND ROBERT L | Director | Dec 31, 2021 | Option Exercise | $52.34 | 148 | 7,746 | 8,809 | Jan 04, 2022, 09:52 PM |
RIGGS RORY B | Director | Dec 31, 2021 | Option Exercise | $52.34 | 300 | 15,702 | 76,815 | Jan 04, 2022, 09:50 PM |
Halstead Michael | EVP and General Counsel | Dec 21, 2021 | Option Exercise | $16.38 | 176,863 | 2,897,494 | 176,863 | Dec 23, 2021, 07:02 PM |
Halstead Michael | EVP and General Counsel | Dec 21, 2021 | Sale | $47.56 | 176,863 | 8,412,278 | 154,243 | Dec 23, 2021, 07:02 PM |
Hineline Lawrence J. | SVP of Finance CFO | Dec 21, 2021 | Option Exercise | $16.81 | 175,000 | 2,941,951 | 175,000 | Dec 23, 2021, 07:00 PM |
Hineline Lawrence J. | SVP of Finance CFO | Dec 21, 2021 | Sale | $47.59 | 175,000 | 8,328,664 | 149,538 | Dec 23, 2021, 07:00 PM |
Neumann Mark | EVP, Chief Commercial Officer | Oct 18, 2021 | Sale | $40.86 | 13,448 | 549,551 | 52,085 | Oct 19, 2021, 04:26 PM |
Mates Sharon | Chairman, President & CEO | Oct 15, 2021 | Option Exercise | $2.84 | 1,075 | 3,053 | 1,102,659 | Oct 18, 2021, 06:00 PM |
Mates Sharon | Chairman, President & CEO | Oct 15, 2021 | Sale | $40.00 | 40,392 | 1,615,680 | 1,101,584 | Oct 18, 2021, 06:00 PM |
Mates Sharon | Chairman, President & CEO | Oct 14, 2021 | Sale | $40.00 | 1,416 | 56,640 | 1,141,976 | Oct 18, 2021, 06:00 PM |
Mates Sharon | Chairman, President & CEO | Oct 18, 2021 | Sale | $40.00 | 8,192 | 327,680 | 1,094,467 | Oct 18, 2021, 06:00 PM |
LERNER RICHARD A | Director | Sep 30, 2021 | Option Exercise | $37.28 | 402 | 14,987 | 96,663 | Oct 04, 2021, 05:43 PM |
RIGGS RORY B | Director | Sep 30, 2021 | Option Exercise | $37.28 | 422 | 15,732 | 76,515 | Oct 04, 2021, 04:24 PM |
VAN NOSTRAND ROBERT L | Director | Sep 30, 2021 | Option Exercise | $37.28 | 215 | 8,015 | 8,661 | Oct 04, 2021, 04:23 PM |
Mates Sharon | Chairman, President & CEO | Aug 23, 2021 | Option Exercise | $2.84 | 10,000 | 28,400 | 1,143,392 | Aug 24, 2021, 04:06 PM |
VAN NOSTRAND ROBERT L | Director | Jun 30, 2021 | Option Exercise | $40.82 | 173 | 7,062 | 8,446 | Jul 02, 2021, 04:55 PM |
RIGGS RORY B | Director | Jun 30, 2021 | Option Exercise | $40.82 | 385 | 15,716 | 76,093 | Jul 02, 2021, 04:52 PM |
LERNER RICHARD A | Director | Jun 30, 2021 | Option Exercise | $40.82 | 367 | 14,981 | 96,261 | Jul 02, 2021, 04:47 PM |
Alafi Christopher D | Director | May 24, 2021 | Sale | $40.47 | 26,575 | 1,075,490 | 142,325 | May 25, 2021, 06:02 PM |
Alafi Christopher D | Director | May 21, 2021 | Sale | $40.00 | 1,100 | 44,000 | 168,900 | May 25, 2021, 06:02 PM |
LERNER RICHARD A | Director | Mar 31, 2021 | Option Exercise | $33.93 | 442 | 14,997 | 95,894 | Apr 02, 2021, 05:31 PM |
MARCUS JOEL S | Director | Mar 02, 2021 | Option Exercise | $26.58 | 20,000 | 531,600 | 87,519 | Mar 04, 2021, 05:43 PM |
MARCUS JOEL S | Director | Mar 02, 2021 | Sale | $34.93 | 15,250 | 532,683 | 72,269 | Mar 04, 2021, 05:43 PM |
Durgam Suresh K. | Chief Medical Officer | Feb 19, 2021 | Sale | $39.25 | 2,734 | 107,310 | 23,304 | Feb 22, 2021, 08:09 PM |
Neumann Mark | EVP, Chief Commercial Officer | Feb 19, 2021 | Sale | $39.22 | 5,184 | 203,308 | 45,939 | Feb 22, 2021, 08:07 PM |
Hineline Lawrence J. | SVP of Finance CFO | Feb 19, 2021 | Sale | $39.23 | 10,442 | 409,625 | 1,200 | Feb 22, 2021, 08:05 PM |
Halstead Michael | EVP and General Counsel | Feb 19, 2021 | Sale | $39.24 | 11,139 | 437,133 | 1,100 | Feb 22, 2021, 08:03 PM |
Mates Sharon | Chairman, President & CEO | Feb 19, 2021 | Sale | $39.23 | 27,847 | 1,092,436 | 1,136,492 | Feb 22, 2021, 08:01 PM |
Durgam Suresh K. | Chief Medical Officer | Jan 11, 2021 | Sale | $32.12 | 4,367 | 140,259 | 17,584 | Jan 12, 2021, 07:07 PM |
Neumann Mark | EVP, Chief Commercial Officer | Jan 11, 2021 | Sale | $32.02 | 9,684 | 310,082 | 39,384 | Jan 12, 2021, 07:06 PM |
Hineline Lawrence J. | SVP of Finance CFO | Jan 11, 2021 | Sale | $32.02 | 19,638 | 628,769 | 2,376 | Jan 12, 2021, 07:05 PM |
Halstead Michael | EVP and General Counsel | Jan 11, 2021 | Sale | $32.03 | 19,638 | 628,978 | 1,936 | Jan 12, 2021, 07:03 PM |
Mates Sharon | Chairman, President & CEO | Jan 11, 2021 | Sale | $32.01 | 41,896 | 1,341,260 | 1,137,977 | Jan 12, 2021, 07:01 PM |
Hineline Lawrence J. | SVP of Finance CFO | Jan 04, 2021 | Sale | $31.31 | 15,810 | 495,008 | 3,450 | Jan 05, 2021, 06:13 PM |
Halstead Michael | EVP and General Counsel | Jan 04, 2021 | Sale | $31.30 | 16,160 | 505,834 | 3,174 | Jan 05, 2021, 06:11 PM |
Mates Sharon | Chairman, President & CEO | Jan 04, 2021 | Sale | $31.30 | 48,341 | 1,513,271 | 1,153,820 | Jan 05, 2021, 06:09 PM |
LERNER RICHARD A | Director | Dec 31, 2020 | Option Exercise | $31.80 | 471 | 14,978 | 95,452 | Jan 05, 2021, 06:07 PM |
VAN NOSTRAND ROBERT L | Director | Dec 31, 2020 | Option Exercise | $31.80 | 222 | 7,060 | 8,065 | Jan 05, 2021, 06:05 PM |
RIGGS RORY B | Director | Dec 31, 2020 | Option Exercise | $31.80 | 495 | 15,741 | 61,477 | Jan 05, 2021, 06:03 PM |
Alafi Christopher D | Director | Dec 31, 2020 | Option Exercise | $31.80 | 495 | 15,741 | 346,331 | Jan 05, 2021, 06:01 PM |
Mates Sharon | Chairman, President & CEO | Dec 18, 2020 | Option Exercise | $2.74 | 34,000 | 93,160 | 1,147,392 | Dec 21, 2020, 04:03 PM |
Halstead Michael | EVP and General Counsel | Nov 17, 2020 | Option Exercise | $13.86 | 75,000 | 1,039,500 | 79,425 | Nov 19, 2020, 08:05 PM |
Halstead Michael | EVP and General Counsel | Nov 17, 2020 | Sale | $27.62 | 79,425 | 2,193,446 | 3,761 | Nov 19, 2020, 08:05 PM |
Hineline Lawrence J. | SVP of Finance CFO | Nov 11, 2020 | Option Exercise | $3.05 | 20,000 | 61,000 | 28,034 | Nov 13, 2020, 05:51 PM |
Hineline Lawrence J. | SVP of Finance CFO | Nov 11, 2020 | Sale | $25.41 | 28,034 | 712,344 | 0 | Nov 13, 2020, 05:51 PM |
Mates Sharon | Chairman, President & CEO | Nov 10, 2020 | Sale | $26.34 | 50,000 | 1,317,101 | 1,132,523 | Nov 12, 2020, 05:51 PM |
Mates Sharon | Chairman, President & CEO | Nov 04, 2020 | Sale | $25.00 | 50,000 | 1,250,000 | 1,163,392 | Nov 06, 2020, 06:00 PM |
Neumann Mark | EVP, Chief Commercial Officer | Oct 16, 2020 | Sale | $26.80 | 6,792 | 182,026 | 28,120 | Oct 16, 2020, 04:04 PM |
VAN NOSTRAND ROBERT L | Director | Sep 30, 2020 | Option Exercise | $25.66 | 276 | 7,082 | 7,843 | Oct 02, 2020, 04:24 PM |
RIGGS RORY B | Director | Sep 30, 2020 | Option Exercise | $25.66 | 613 | 15,730 | 60,982 | Oct 02, 2020, 04:22 PM |
LERNER RICHARD A | Director | Sep 30, 2020 | Option Exercise | $25.66 | 584 | 14,985 | 94,981 | Oct 02, 2020, 04:17 PM |
Alafi Christopher D | Director | Sep 30, 2020 | Option Exercise | $25.66 | 613 | 15,730 | 345,836 | Oct 02, 2020, 04:13 PM |
Alafi Christopher D | Director | Sep 14, 2020 | Buy | $29.60 | 49,500 | 1,465,200 | 4,743,770 | Sep 14, 2020, 05:03 PM |
Hineline Lawrence J. | SVP of Finance CFO | Sep 09, 2020 | Option Exercise | $12.73 | 26,983 | 343,494 | 50,017 | Sep 11, 2020, 07:08 PM |
Hineline Lawrence J. | SVP of Finance CFO | Sep 09, 2020 | Sale | $31.14 | 41,983 | 1,307,351 | 8,034 | Sep 11, 2020, 07:08 PM |
Alafi Christopher D | Director | Sep 11, 2020 | Buy | $28.08 | 21,000 | 589,680 | 4,694,270 | Sep 11, 2020, 04:15 PM |
VAN NOSTRAND ROBERT L | Director | Jun 30, 2020 | Option Exercise | $25.67 | 275 | 7,059 | 7,567 | Jul 02, 2020, 07:12 PM |
LERNER RICHARD A | Director | Jun 30, 2020 | Option Exercise | $25.67 | 584 | 14,991 | 94,397 | Jul 02, 2020, 07:05 PM |
RIGGS RORY B | Director | Jun 30, 2020 | Option Exercise | $25.67 | 613 | 15,736 | 60,369 | Jul 02, 2020, 07:02 PM |
Alafi Christopher D | Director | Jun 30, 2020 | Option Exercise | $25.67 | 613 | 15,736 | 345,223 | Jul 02, 2020, 06:58 PM |
MARCUS JOEL S | Director | May 14, 2020 | Sale | $20.04 | 9,602 | 192,424 | 39,140 | May 15, 2020, 05:37 PM |
MARCUS JOEL S | Director | May 11, 2020 | Sale | $19.95 | 50,000 | 997,500 | 48,742 | May 13, 2020, 07:48 PM |
MARCUS JOEL S | Director | May 13, 2020 | Sale | $20.63 | 7,297 | 150,537 | 14,374 | May 13, 2020, 07:48 PM |
LERNER RICHARD A | Director | May 11, 2020 | Option Exercise | $2.74 | 25,000 | 68,500 | 97,313 | May 13, 2020, 05:20 PM |
LERNER RICHARD A | Director | May 11, 2020 | Sale | $20.50 | 3,500 | 71,750 | 93,813 | May 13, 2020, 05:20 PM |
Alafi Christopher D | Director | Mar 31, 2020 | Option Exercise | $15.37 | 1,024 | 15,739 | 344,610 | Apr 02, 2020, 06:05 PM |
LERNER RICHARD A | Director | Mar 31, 2020 | Option Exercise | $15.37 | 975 | 14,986 | 72,313 | Apr 02, 2020, 06:01 PM |
VAN NOSTRAND ROBERT L | Director | Mar 31, 2020 | Option Exercise | $15.37 | 460 | 7,070 | 7,292 | Apr 02, 2020, 05:55 PM |
RIGGS RORY B | Director | Mar 31, 2020 | Option Exercise | $15.37 | 1,024 | 15,739 | 45,751 | Apr 02, 2020, 05:50 PM |
Halstead Michael | EVP and General Counsel | Jan 24, 2020 | Option Exercise | $23.61 | 3,809 | 89,930 | 4,425 | Jan 28, 2020, 09:31 PM |
Hineline Lawrence J. | SVP of Finance CFO | Jan 24, 2020 | Option Exercise | $23.61 | 3,809 | 89,930 | 23,034 | Jan 28, 2020, 09:30 PM |
Mates Sharon | Chairman, President & CEO | Jan 24, 2020 | Option Exercise | $23.61 | 9,323 | 220,116 | 1,213,392 | Jan 28, 2020, 09:28 PM |
LERNER RICHARD A | Director | Dec 31, 2019 | Option Exercise | $34.31 | 400 | 13,724 | 71,338 | Jan 16, 2020, 06:13 PM |
Satlin Andrew | EVP and Chief Medical Officer | Jan 09, 2020 | Sale | $26.16 | 11,573 | 302,750 | 11,338 | Jan 10, 2020, 09:14 PM |
Neumann Mark | EVP, Chief Commercial Officer | Jan 08, 2020 | Option Exercise | $26.34 | 6,157 | 162,175 | 21,464 | Jan 10, 2020, 09:11 PM |
Mates Sharon | Chairman, President & CEO | Jan 09, 2020 | Sale | $26.16 | 41,895 | 1,095,973 | 1,204,707 | Jan 10, 2020, 09:09 PM |
Halstead Michael | EVP and General Counsel | Jan 09, 2020 | Sale | $26.16 | 19,638 | 513,730 | 191 | Jan 10, 2020, 09:06 PM |
Hineline Lawrence J. | SVP of Finance CFO | Jan 09, 2020 | Sale | $26.16 | 19,638 | 513,730 | 18,800 | Jan 10, 2020, 09:03 PM |
Mates Sharon | Chairman, President & CEO | Jan 08, 2020 | Option Exercise | $2.74 | 60,000 | 164,400 | 1,246,602 | Jan 08, 2020, 09:11 PM |
Mates Sharon | Chairman, President & CEO | Jan 06, 2020 | Sale | $30.28 | 45,598 | 1,380,880 | 1,182,366 | Jan 08, 2020, 09:11 PM |
Halstead Michael | EVP and General Counsel | Jan 06, 2020 | Sale | $30.34 | 21,458 | 651,007 | 17,704 | Jan 08, 2020, 09:02 PM |
Hineline Lawrence J. | SVP of Finance CFO | Jan 06, 2020 | Sale | $30.29 | 21,458 | 650,003 | 36,391 | Jan 08, 2020, 09:00 PM |
Halstead Michael | EVP and General Counsel | Jan 02, 2020 | Sale | $32.43 | 7,807 | 253,214 | 6,375 | Jan 03, 2020, 09:17 PM |
Hineline Lawrence J. | SVP of Finance CFO | Jan 02, 2020 | Sale | $32.43 | 7,807 | 253,165 | 25,807 | Jan 03, 2020, 09:16 PM |
Mates Sharon | Chairman, President & CEO | Dec 31, 2019 | Option Exercise | $2.74 | 6,000 | 16,440 | 1,162,185 | Jan 03, 2020, 09:14 PM |
Mates Sharon | Chairman, President & CEO | Jan 02, 2020 | Sale | $32.45 | 17,478 | 567,230 | 1,158,485 | Jan 03, 2020, 09:14 PM |
VAN NOSTRAND ROBERT L | Director | Dec 31, 2019 | Option Exercise | $34.31 | 170 | 5,833 | 6,832 | Jan 03, 2020, 09:13 PM |
RIGGS RORY B | Director | Dec 31, 2019 | Option Exercise | $34.31 | 422 | 14,479 | 44,727 | Jan 03, 2020, 09:12 PM |
Alafi Christopher D | Director | Dec 31, 2019 | Option Exercise | $34.31 | 422 | 14,479 | 343,586 | Jan 03, 2020, 09:11 PM |
Hineline Lawrence J. | SVP of Finance CFO | Dec 23, 2019 | Option Exercise | $2.74 | 9,600 | 26,304 | 34,832 | Dec 26, 2019, 04:06 PM |
Hineline Lawrence J. | SVP of Finance CFO | Dec 23, 2019 | Sale | $25.50 | 15,032 | 383,316 | 25,232 | Dec 26, 2019, 04:06 PM |
Neumann Mark | EVP, Chief Commercial Officer | Oct 16, 2019 | Sale | $8.25 | 6,774 | 55,886 | 6,674 | Oct 17, 2019, 04:50 PM |
RIGGS RORY B | Director | Sep 30, 2019 | Option Exercise | $7.47 | 1,941 | 14,499 | 44,305 | Oct 02, 2019, 05:37 PM |
LERNER RICHARD A | Director | Sep 30, 2019 | Option Exercise | $7.47 | 1,840 | 13,745 | 70,938 | Oct 02, 2019, 05:35 PM |
VAN NOSTRAND ROBERT L | Director | Sep 30, 2019 | Option Exercise | $7.47 | 780 | 5,827 | 6,662 | Oct 02, 2019, 05:32 PM |
Alafi Christopher D | Director | Sep 30, 2019 | Option Exercise | $7.47 | 1,941 | 14,499 | 343,164 | Oct 02, 2019, 05:29 PM |
Alafi Christopher D | Director | Sep 10, 2019 | Buy | $10.26 | 485,000 | 4,974,678 | 4,673,270 | Sep 11, 2019, 04:30 PM |
Alafi Christopher D | Director | Aug 30, 2019 | Buy | $8.52 | 125,000 | 1,065,212 | 4,188,270 | Sep 04, 2019, 06:24 PM |
VAN NOSTRAND ROBERT L | Director | Jun 28, 2019 | Option Exercise | $12.98 | 449 | 5,828 | 5,882 | Jul 02, 2019, 05:17 PM |
LERNER RICHARD A | Director | Jun 28, 2019 | Option Exercise | $12.98 | 1,059 | 13,746 | 69,098 | Jul 02, 2019, 05:12 PM |
RIGGS RORY B | Director | Jun 28, 2019 | Option Exercise | $12.98 | 1,117 | 14,499 | 42,364 | Jul 02, 2019, 05:03 PM |
Alafi Christopher D | Director | Jun 28, 2019 | Option Exercise | $12.98 | 1,117 | 14,499 | 341,223 | Jul 02, 2019, 12:00 AM |
Alafi Christopher D | Director | Nov 22, 2017 | Buy | $15.55 | 10,000 | 155,500 | 3,963,270 | Jun 19, 2019, 05:48 PM |
Alafi Christopher D | Director | Jun 12, 2019 | Buy | $11.73 | 170,000 | 1,993,793 | 170,000 | Jun 14, 2019, 05:23 PM |
MARCUS JOEL S | Director | May 29, 2019 | Option Exercise | $12.45 | 20,000 | 249,000 | 41,671 | May 31, 2019, 04:35 PM |
Alafi Christopher D | Director | May 14, 2019 | Buy | $12.56 | 100,000 | 1,256,350 | 4,053,270 | May 15, 2019, 06:03 PM |
Alafi Christopher D | Director | Mar 31, 2019 | Option Exercise | $12.18 | 1,190 | 14,494 | 750,106 | Apr 02, 2019, 07:03 PM |
VAN NOSTRAND ROBERT L | Director | Mar 31, 2019 | Option Exercise | $12.18 | 478 | 5,822 | 5,433 | Apr 02, 2019, 06:59 PM |
RIGGS RORY B | Director | Mar 31, 2019 | Option Exercise | $12.18 | 1,190 | 14,494 | 41,247 | Apr 02, 2019, 06:56 PM |
LERNER RICHARD A | Director | Mar 31, 2019 | Option Exercise | $12.18 | 1,128 | 13,739 | 68,039 | Apr 02, 2019, 06:52 PM |
Hineline Lawrence J. | SVP of Finance CFO | Feb 27, 2019 | Option Exercise | $2.74 | 10,400 | 28,496 | 26,232 | Mar 01, 2019, 07:41 PM |
Hineline Lawrence J. | SVP of Finance CFO | Feb 27, 2019 | Sale | $15.00 | 1,000 | 15,000 | 25,232 | Mar 01, 2019, 07:41 PM |
Mates Sharon | Chairman, President & CEO | Jan 07, 2019 | Sale | $12.43 | 6,604 | 82,088 | 1,138,707 | Jan 08, 2019, 09:28 PM |
Mates Sharon | Chairman, President & CEO | Jan 04, 2019 | Sale | $11.45 | 45,598 | 522,222 | 1,152,850 | Jan 08, 2019, 09:28 PM |
Halstead Michael | EVP and General Counsel | Jan 07, 2019 | Sale | $12.42 | 3,108 | 38,601 | 191 | Jan 08, 2019, 09:24 PM |
Halstead Michael | EVP and General Counsel | Jan 04, 2019 | Sale | $11.46 | 21,458 | 245,817 | 8,697 | Jan 08, 2019, 09:24 PM |
Hineline Lawrence J. | SVP of Finance CFO | Jan 07, 2019 | Sale | $12.42 | 3,108 | 38,601 | 17,032 | Jan 08, 2019, 09:21 PM |
Hineline Lawrence J. | SVP of Finance CFO | Jan 04, 2019 | Sale | $11.45 | 21,458 | 245,782 | 21,882 | Jan 08, 2019, 09:21 PM |
Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | Jan 04, 2019 | Sale | $11.47 | 9,564 | 109,704 | 29,844 | Jan 08, 2019, 09:19 PM |
Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | Jan 07, 2019 | Sale | $12.29 | 592 | 7,276 | 27,068 | Jan 08, 2019, 09:19 PM |
Davis Robert E | SVP, Chief Scientific Officer | Jan 04, 2019 | Sale | $11.46 | 9,564 | 109,630 | 46,691 | Jan 08, 2019, 09:16 PM |
Mates Sharon | Chairman, President & CEO | Jan 02, 2019 | Sale | $11.09 | 17,478 | 193,831 | 1,138,707 | Jan 03, 2019, 09:02 PM |
Halstead Michael | EVP and General Counsel | Jan 02, 2019 | Sale | $11.09 | 7,807 | 86,580 | 191 | Jan 03, 2019, 08:58 PM |
Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | Jan 02, 2019 | Sale | $11.10 | 4,834 | 53,657 | 16,861 | Jan 03, 2019, 08:46 PM |
Davis Robert E | SVP, Chief Scientific Officer | Jan 02, 2019 | Sale | $11.11 | 4,834 | 53,706 | 34,744 | Jan 03, 2019, 08:42 PM |
Hineline Lawrence J. | SVP of Finance CFO | Jan 02, 2019 | Sale | $11.09 | 7,807 | 86,580 | 17,032 | Jan 03, 2019, 08:23 PM |
VAN NOSTRAND ROBERT L | Director | Dec 31, 2018 | Option Exercise | $11.39 | 512 | 5,832 | 4,955 | Jan 03, 2019, 08:19 PM |
RIGGS RORY B | Director | Dec 31, 2018 | Option Exercise | $11.39 | 1,273 | 14,499 | 40,057 | Jan 03, 2019, 08:15 PM |
LERNER RICHARD A | Director | Dec 31, 2018 | Option Exercise | $11.39 | 1,207 | 13,748 | 11,430 | Jan 03, 2019, 08:11 PM |
Alafi Christopher D | Director | Dec 31, 2018 | Option Exercise | $11.39 | 1,273 | 14,499 | 748,916 | Jan 03, 2019, 08:05 PM |
Mates Sharon | Chairman, President & CEO | Dec 10, 2018 | Option Exercise | $1.50 | 50,000 | 75,000 | 1,138,707 | Dec 11, 2018, 05:55 PM |
Davis Robert E | SVP, Chief Scientific Officer | Dec 06, 2018 | Sale | $13.53 | 899 | 12,163 | 30,256 | Dec 07, 2018, 04:44 PM |
MARCUS JOEL S | Director | Nov 12, 2018 | Sale | $17.94 | 7,000 | 125,580 | 78,742 | Nov 13, 2018, 05:34 PM |
MARCUS JOEL S | Director | Nov 09, 2018 | Sale | $18.24 | 25,000 | 456,000 | 85,742 | Nov 13, 2018, 05:34 PM |
LERNER RICHARD A | Director | Oct 22, 2018 | Option Exercise | $1.50 | 12,500 | 18,750 | 66,911 | Oct 24, 2018, 04:33 PM |
LERNER RICHARD A | Director | Sep 30, 2018 | Option Exercise | $21.70 | 633 | 13,736 | 54,411 | Oct 02, 2018, 08:11 PM |
RIGGS RORY B | Director | Sep 30, 2018 | Option Exercise | $21.70 | 668 | 14,496 | 38,784 | Oct 02, 2018, 08:08 PM |
VAN NOSTRAND ROBERT L | Director | Sep 30, 2018 | Option Exercise | $21.70 | 268 | 5,816 | 4,443 | Oct 02, 2018, 08:06 PM |
Alafi Christopher D | Director | Sep 30, 2018 | Option Exercise | $21.70 | 668 | 14,496 | 747,643 | Oct 02, 2018, 08:01 PM |
LERNER RICHARD A | Director | Jun 29, 2018 | Option Exercise | $17.67 | 778 | 13,747 | 53,778 | Jul 03, 2018, 04:27 PM |
Alafi Christopher D | Director | Jun 29, 2018 | Option Exercise | $17.67 | 820 | 14,489 | 746,975 | Jul 03, 2018, 12:00 AM |
VAN NOSTRAND ROBERT L | Director | Jun 29, 2018 | Option Exercise | $17.67 | 282 | 4,983 | 4,175 | Jul 03, 2018, 12:00 AM |
RIGGS RORY B | Director | Jun 29, 2018 | Option Exercise | $17.67 | 820 | 14,489 | 38,116 | Jul 03, 2018, 12:00 AM |
VAN NOSTRAND ROBERT L | Director | Mar 30, 2018 | Option Exercise | $21.05 | 237 | 4,989 | 3,893 | Apr 03, 2018, 04:19 PM |
RIGGS RORY B | Director | Mar 30, 2018 | Option Exercise | $21.05 | 688 | 14,482 | 37,296 | Apr 03, 2018, 12:00 AM |
LERNER RICHARD A | Director | Mar 30, 2018 | Option Exercise | $21.05 | 653 | 13,746 | 10,223 | Apr 03, 2018, 12:00 AM |
Alafi Christopher D | Director | Mar 30, 2018 | Option Exercise | $21.05 | 688 | 14,482 | 746,155 | Apr 03, 2018, 12:00 AM |
Hineline Lawrence J. | VP of Finance CFO | Feb 16, 2018 | Sale | $20.01 | 16,319 | 326,543 | 17,032 | Feb 20, 2018, 04:38 PM |
Hineline Lawrence J. | VP of Finance CFO | Feb 15, 2018 | Sale | $20.03 | 33,381 | 668,621 | 33,351 | Feb 20, 2018, 04:38 PM |
Halstead Michael | SVP and General Counsel | Jan 22, 2018 | Sale | $18.03 | 25,500 | 459,765 | 191 | Jan 24, 2018, 07:11 PM |
Vanover Kimberly E. | SVP, Clinical Development | Jan 08, 2018 | Sale | $17.46 | 772 | 13,479 | 12,373 | Jan 10, 2018, 09:05 PM |
Mates Sharon | Chairman, President & CEO | Jan 08, 2018 | Sale | $17.48 | 6,604 | 115,438 | 1,088,707 | Jan 10, 2018, 09:01 PM |
Mates Sharon | Chairman, President & CEO | Jan 05, 2018 | Sale | $17.08 | 11,257 | 192,270 | 1,095,311 | Jan 05, 2018, 08:19 PM |
Vanover Kimberly E. | SVP, Clinical Development | Jan 05, 2018 | Sale | $17.37 | 1,185 | 20,583 | 13,145 | Jan 05, 2018, 08:14 PM |
Davis Robert E | SVP, Chief Scientific Officer | Jan 04, 2018 | Sale | $15.60 | 1,115 | 17,394 | 29,397 | Jan 05, 2018, 08:09 PM |
Hineline Lawrence J. | VP of Finance CFO | Jan 04, 2018 | Sale | $15.67 | 3,192 | 50,019 | 68,602 | Jan 05, 2018, 08:06 PM |
Hineline Lawrence J. | VP of Finance CFO | Jan 05, 2018 | Sale | $17.49 | 1,870 | 32,706 | 66,732 | Jan 05, 2018, 08:06 PM |
Halstead Michael | SVP and General Counsel | Jan 05, 2018 | Sale | $17.49 | 1,560 | 27,284 | 25,691 | Jan 05, 2018, 08:03 PM |
Halstead Michael | SVP and General Counsel | Jan 04, 2018 | Sale | $15.75 | 2,660 | 41,895 | 27,251 | Jan 05, 2018, 08:03 PM |
VAN NOSTRAND ROBERT L | Director | Dec 29, 2017 | Option Exercise | $14.48 | 345 | 4,996 | 3,656 | Jan 03, 2018, 06:10 PM |
RIGGS RORY B | Director | Dec 29, 2017 | Option Exercise | $14.48 | 1,001 | 14,494 | 36,608 | Jan 03, 2018, 06:05 PM |
LERNER RICHARD A | Director | Dec 29, 2017 | Option Exercise | $14.48 | 949 | 13,742 | 9,570 | Jan 03, 2018, 06:01 PM |
Alafi Christopher D | Director | Dec 29, 2017 | Option Exercise | $14.48 | 1,001 | 14,494 | 745,467 | Jan 03, 2018, 05:59 PM |
VAN NOSTRAND ROBERT L | Director | Dec 29, 2017 | Buy | $14.48 | 345 | 4,996 | 3,656 | Jan 03, 2018, 04:31 PM |
LERNER RICHARD A | Director | Dec 29, 2017 | Buy | $14.48 | 949 | 13,742 | 9,570 | Jan 03, 2018, 04:29 PM |
RIGGS RORY B | Director | Dec 29, 2017 | Buy | $14.48 | 1,001 | 14,494 | 36,608 | Jan 03, 2018, 12:00 AM |
Alafi Christopher D | Director | Dec 29, 2017 | Buy | $14.48 | 1,001 | 14,494 | 745,467 | Jan 03, 2018, 12:00 AM |
LERNER RICHARD A | Director | Dec 11, 2017 | Option Exercise | $1.50 | 12,500 | 18,750 | 60,000 | Dec 13, 2017, 04:52 PM |
LERNER RICHARD A | Director | Dec 11, 2017 | Sale | $15.09 | 7,000 | 105,630 | 53,000 | Dec 13, 2017, 04:52 PM |
Davis Robert E | SVP, Chief Scientific Officer | Dec 05, 2017 | Sale | $15.00 | 650 | 9,750 | 27,864 | Dec 06, 2017, 06:33 PM |
Alafi Christopher D | Director | Nov 22, 2017 | Buy | $15.55 | 10,000 | 155,500 | 744,466 | Nov 27, 2017, 04:31 PM |
Mates Sharon | Chairman, President & CEO | Oct 30, 2017 | Option Exercise | $1.50 | 18,750 | 28,125 | 1,107,457 | Nov 01, 2017, 08:04 PM |
Mates Sharon | Chairman, President & CEO | Oct 30, 2017 | Sale | $15.75 | 18,750 | 295,313 | 1,088,707 | Nov 01, 2017, 08:04 PM |
ALAFI MOSHE | 10% Owner | Oct 02, 2017 | Buy | $15.50 | 258,065 | 4,000,008 | 3,953,270 | Oct 03, 2017, 06:11 PM |
Alafi Christopher D | Director | Oct 02, 2017 | Buy | $15.50 | 258,065 | 4,000,008 | 3,953,270 | Oct 03, 2017, 06:10 PM |
ALAFI CAPITAL CO LLC | 10% Owner | Oct 02, 2017 | Buy | $15.50 | 258,065 | 4,000,008 | 3,953,270 | Oct 03, 2017, 06:08 PM |
MARCUS JOEL S | Director | Jan 26, 2017 | Option Exercise | $2.60 | 95,000 | 247,450 | 116,671 | Jan 30, 2017, 06:13 PM |
Vanover Kimberly E. | SVP, Clinical Development | Jan 05, 2017 | Sale | $16.59 | 800 | 13,272 | 10,128 | Jan 09, 2017, 05:34 PM |
Mates Sharon | Chairman, President & CEO | Jan 05, 2017 | Sale | $16.55 | 4,081 | 67,541 | 1,088,707 | Jan 09, 2017, 05:31 PM |
Hineline Lawrence J. | VP of Finance CFO | Jan 05, 2017 | Sale | $16.58 | 1,918 | 31,800 | 63,389 | Jan 09, 2017, 05:29 PM |
Halstead Michael | SVP and General Counsel | Jan 05, 2017 | Sale | $16.55 | 1,601 | 26,497 | 21,506 | Jan 09, 2017, 05:27 PM |
Vanover Kimberly E. | SVP, Clinical Development | Dec 15, 2016 | Option Exercise | $1.46 | 18,750 | 27,425 | 12,500 | Dec 19, 2016, 05:50 PM |
Vanover Kimberly E. | SVP, Clinical Development | Dec 15, 2016 | Sale | $15.23 | 9,375 | 142,773 | 9,375 | Dec 19, 2016, 05:50 PM |
ALAFI MOSHE | 10% Owner | Dec 07, 2016 | Buy | $16.14 | 20,826 | 336,038 | 3,695,205 | Dec 07, 2016, 04:35 PM |
ALAFI MOSHE | 10% Owner | Dec 06, 2016 | Buy | $16.33 | 44,174 | 721,445 | 3,674,379 | Dec 07, 2016, 04:35 PM |
Alafi Christopher D | Director | Dec 07, 2016 | Buy | $16.14 | 20,826 | 336,038 | 3,695,205 | Dec 07, 2016, 04:32 PM |
Alafi Christopher D | Director | Dec 06, 2016 | Buy | $16.33 | 44,174 | 721,445 | 3,674,379 | Dec 07, 2016, 04:32 PM |
ALAFI CAPITAL CO LLC | 10% Owner | Dec 07, 2016 | Buy | $16.14 | 20,826 | 336,038 | 3,695,205 | Dec 07, 2016, 04:21 PM |
ALAFI CAPITAL CO LLC | 10% Owner | Dec 06, 2016 | Buy | $16.33 | 44,174 | 721,445 | 3,674,379 | Dec 07, 2016, 04:21 PM |
ALAFI MOSHE | 10% Owner | Nov 14, 2016 | Buy | $14.50 | 34,000 | 492,969 | 3,630,205 | Nov 17, 2016, 04:35 PM |
ALAFI CAPITAL CO LLC | 10% Owner | Nov 14, 2016 | Buy | $14.50 | 34,000 | 492,969 | 3,630,205 | Nov 17, 2016, 04:34 PM |
Alafi Christopher D | Director | Nov 14, 2016 | Buy | $14.50 | 34,000 | 492,969 | 3,630,205 | Nov 17, 2016, 04:32 PM |
RIGGS RORY B | Director | Feb 05, 2014 | Buy | $17.50 | 14,285 | 249,988 | 26,091 | Apr 20, 2016, 04:30 PM |
RIGGS RORY B | Director | Feb 05, 2014 | Buy | $17.50 | 14,286 | 250,005 | 226,670 | Apr 20, 2016, 04:30 PM |
Alafi Christopher D | Director | Feb 29, 2016 | Buy | $29.70 | 100,000 | 2,970,300 | 728,828 | Feb 29, 2016, 05:32 PM |
LERNER RICHARD A | Director | Feb 18, 2016 | Option Exercise | $1.36 | 10,000 | 13,600 | 47,500 | Feb 19, 2016, 04:25 PM |
VAN NOSTRAND ROBERT L | Director | Dec 31, 2015 | Option Exercise | $53.79 | 69 | 3,712 | 1,365 | Jan 05, 2016, 07:09 PM |
RIGGS RORY B | Director | Dec 31, 2015 | Option Exercise | $53.79 | 197 | 10,597 | 15,679 | Jan 05, 2016, 05:13 PM |
MARCUS JOEL S | Director | Dec 31, 2015 | Option Exercise | $53.79 | 199 | 10,704 | 18,921 | Jan 05, 2016, 05:11 PM |
Alafi Christopher D | Director | Dec 31, 2015 | Option Exercise | $53.79 | 195 | 10,489 | 628,828 | Jan 05, 2016, 05:00 PM |
LERNER RICHARD A | Director | Dec 31, 2015 | Option Exercise | $53.79 | 188 | 10,113 | 3,266 | Jan 05, 2016, 04:59 PM |
Mates Sharon | Chairman, President & CEO | Dec 11, 2015 | Option Exercise | $1.12 | 68,750 | 77,125 | 1,137,685 | Dec 15, 2015, 08:27 PM |
Mates Sharon | Chairman, President & CEO | Dec 11, 2015 | Sale | $53.87 | 51,500 | 2,774,441 | 1,107,639 | Dec 15, 2015, 08:27 PM |
Hineline Lawrence J. | VP of Finance CFO | Dec 15, 2015 | Option Exercise | $1.45 | 35,000 | 50,750 | 74,700 | Dec 15, 2015, 08:25 PM |
Hineline Lawrence J. | VP of Finance CFO | Dec 14, 2015 | Option Exercise | $0.60 | 7,500 | 4,500 | 72,200 | Dec 15, 2015, 08:25 PM |
Hineline Lawrence J. | VP of Finance CFO | Nov 24, 2015 | Option Exercise | $0.60 | 5,000 | 3,000 | 64,700 | Dec 15, 2015, 08:25 PM |
Hineline Lawrence J. | VP of Finance CFO | Dec 15, 2015 | Sale | $51.97 | 22,500 | 1,169,226 | 63,464 | Dec 15, 2015, 08:25 PM |
Hineline Lawrence J. | VP of Finance CFO | Dec 14, 2015 | Sale | $50.94 | 22,500 | 1,146,140 | 62,307 | Dec 15, 2015, 08:25 PM |
MARCUS JOEL S | Director | Dec 08, 2015 | Sale | $54.80 | 22,700 | 1,243,960 | 1,191,156 | Dec 08, 2015, 05:30 PM |
MARCUS JOEL S | Director | Dec 07, 2015 | Sale | $53.17 | 40,000 | 2,126,628 | 1,238,781 | Dec 08, 2015, 05:30 PM |
MARCUS JOEL S | Director | Dec 04, 2015 | Sale | $55.96 | 30,000 | 1,678,800 | 1,253,856 | Dec 08, 2015, 05:30 PM |
Hineline Lawrence J. | VP of Finance CFO | Nov 24, 2015 | Sale | $55.00 | 5,000 | 275,000 | 59,700 | Nov 27, 2015, 08:29 AM |
Fienberg Allen A. | VP of Business Development | Sep 09, 2015 | Option Exercise | $1.36 | 12,500 | 17,000 | 295,000 | Sep 11, 2015, 04:53 PM |
Fienberg Allen A. | VP of Business Development | Aug 21, 2015 | Sale | $30.30 | 200 | 6,060 | 197,823 | Sep 11, 2015, 04:53 PM |
Fienberg Allen A. | VP of Business Development | Aug 19, 2015 | Sale | $30.30 | 10,000 | 303,000 | 198,023 | Sep 11, 2015, 04:53 PM |
Wennogle Lawrence P. | Vice President, Drug Discovery | Jun 08, 2015 | Sale | $26.84 | 25,000 | 671,000 | 126,500 | Jun 09, 2015, 05:04 PM |
Wennogle Lawrence P. | Vice President, Drug Discovery | May 19, 2015 | Option Exercise | $1.23 | 47,500 | 58,250 | 151,500 | May 20, 2015, 05:19 PM |
Fienberg Allen A. | VP of Business Development | Mar 31, 2015 | Option Exercise | $0.60 | 12,500 | 7,500 | 282,500 | Apr 02, 2015, 04:59 PM |
MARCUS JOEL S | Director | Mar 31, 2015 | Option Exercise | $1.23 | 15,000 | 18,400 | 18,118 | Apr 02, 2015, 04:58 PM |
Alafi Christopher D | Director | Mar 11, 2015 | Buy | $24.00 | 625,000 | 15,000,000 | 627,604 | Mar 12, 2015, 06:24 PM |
Fienberg Allen A. | VP of Business Development | Jan 14, 2015 | Sale | $19.00 | 5,000 | 95,000 | 270,000 | Jan 16, 2015, 04:31 PM |
Hineline Lawrence J. | VP of Finance CFO | Dec 09, 2014 | Sale | $16.52 | 11,535 | 190,558 | 64,700 | Dec 10, 2014, 05:11 PM |
Hineline Lawrence J. | VP of Finance CFO | Dec 08, 2014 | Sale | $16.91 | 10,965 | 185,418 | 76,235 | Dec 10, 2014, 05:11 PM |
Hineline Lawrence J. | VP of Finance CFO | Dec 02, 2014 | Option Exercise | $0.50 | 37,200 | 18,600 | 87,200 | Dec 03, 2014, 05:43 PM |
Alafi Christopher D | Director | Dec 01, 2014 | Buy | $14.75 | 1,422 | 20,975 | 3,596,205 | Dec 03, 2014, 05:42 PM |
ALAFI MOSHE | 10% Owner | Dec 01, 2014 | Buy | $14.75 | 1,422 | 20,975 | 3,596,205 | Dec 03, 2014, 05:40 PM |
ALAFI CAPITAL CO LLC | 10% Owner | Dec 01, 2014 | Buy | $14.75 | 1,422 | 20,975 | 3,596,205 | Dec 03, 2014, 05:39 PM |
ALAFI CAPITAL CO LLC | 10% Owner | Nov 28, 2014 | Buy | $14.75 | 35,000 | 516,250 | 3,594,783 | Nov 28, 2014, 04:42 PM |
ALAFI MOSHE | 10% Owner | Nov 28, 2014 | Buy | $14.75 | 35,000 | 516,250 | 3,594,783 | Nov 28, 2014, 04:38 PM |
Alafi Christopher D | Director | Nov 28, 2014 | Buy | $14.75 | 35,000 | 516,250 | 3,594,783 | Nov 28, 2014, 04:36 PM |
Mates Sharon | Chairman, President & CEO | Nov 25, 2014 | Option Exercise | $0.50 | 50,000 | 25,000 | 1,103,935 | Nov 28, 2014, 04:31 PM |
Mates Sharon | Chairman, President & CEO | Nov 28, 2014 | Sale | $14.75 | 35,000 | 516,250 | 1,068,935 | Nov 28, 2014, 04:31 PM |
Alafi Christopher D | Director | Nov 19, 2014 | Buy | $14.25 | 1,034 | 14,735 | 3,559,783 | Nov 21, 2014, 06:04 PM |
ALAFI MOSHE | 10% Owner | Nov 19, 2014 | Buy | $14.25 | 1,034 | 14,735 | 3,559,783 | Nov 21, 2014, 06:00 PM |
ALAFI CAPITAL CO LLC | 10% Owner | Nov 19, 2014 | Buy | $14.25 | 1,034 | 14,735 | 3,559,783 | Nov 21, 2014, 05:58 PM |
Alafi Christopher D | Director | Nov 18, 2014 | Buy | $14.23 | 3,531 | 50,246 | 3,558,749 | Nov 18, 2014, 05:46 PM |
Alafi Christopher D | Director | Nov 14, 2014 | Buy | $15.07 | 133 | 2,004 | 3,555,218 | Nov 18, 2014, 05:46 PM |
ALAFI MOSHE | 10% Owner | Nov 18, 2014 | Buy | $14.23 | 3,531 | 50,246 | 3,558,749 | Nov 18, 2014, 05:45 PM |
ALAFI MOSHE | 10% Owner | Nov 14, 2014 | Buy | $15.07 | 133 | 2,004 | 3,555,218 | Nov 18, 2014, 05:45 PM |
ALAFI CAPITAL CO LLC | 10% Owner | Nov 18, 2014 | Buy | $14.23 | 3,531 | 50,246 | 3,558,749 | Nov 18, 2014, 05:43 PM |
ALAFI CAPITAL CO LLC | 10% Owner | Nov 14, 2014 | Buy | $15.07 | 133 | 2,004 | 3,555,218 | Nov 18, 2014, 05:43 PM |
Alafi Christopher D | Director | Nov 13, 2014 | Buy | $15.12 | 2,200 | 33,264 | 3,555,085 | Nov 13, 2014, 05:04 PM |
Alafi Christopher D | Director | Nov 12, 2014 | Buy | $15.23 | 5,000 | 76,150 | 3,552,885 | Nov 13, 2014, 05:04 PM |
Alafi Christopher D | Director | Nov 11, 2014 | Buy | $15.55 | 5,000 | 77,750 | 3,547,885 | Nov 13, 2014, 05:04 PM |
ALAFI MOSHE | 10% Owner | Nov 11, 2014 | Buy | $15.55 | 5,000 | 77,750 | 3,547,885 | Nov 13, 2014, 05:01 PM |
ALAFI MOSHE | 10% Owner | Nov 13, 2014 | Buy | $15.12 | 2,200 | 33,264 | 3,555,085 | Nov 13, 2014, 05:01 PM |
ALAFI MOSHE | 10% Owner | Nov 12, 2014 | Buy | $15.23 | 5,000 | 76,150 | 3,552,885 | Nov 13, 2014, 05:01 PM |
ALAFI CAPITAL CO LLC | 10% Owner | Nov 13, 2014 | Buy | $15.12 | 2,200 | 33,264 | 3,555,085 | Nov 13, 2014, 04:59 PM |
ALAFI CAPITAL CO LLC | 10% Owner | Nov 12, 2014 | Buy | $15.23 | 5,000 | 76,150 | 3,552,885 | Nov 13, 2014, 04:59 PM |
ALAFI CAPITAL CO LLC | 10% Owner | Nov 11, 2014 | Buy | $15.55 | 5,000 | 77,750 | 3,547,885 | Nov 13, 2014, 04:59 PM |
Halstead Michael | SVP and General Counsel | Nov 06, 2014 | Buy | $15.47 | 13,000 | 201,110 | 20,000 | Nov 06, 2014, 04:53 PM |
Halstead Michael | SVP and General Counsel | Nov 05, 2014 | Buy | $15.21 | 7,000 | 106,470 | 7,000 | Nov 06, 2014, 04:53 PM |
Wennogle Lawrence P. | Vice President, Drug Discovery | Oct 16, 2014 | Sale | $15.00 | 5,152 | 77,280 | 104,000 | Oct 17, 2014, 05:00 PM |
Wennogle Lawrence P. | Vice President, Drug Discovery | Oct 13, 2014 | Sale | $15.00 | 1,600 | 24,000 | 111,156 | Oct 15, 2014, 04:52 PM |
Wennogle Lawrence P. | Vice President, Drug Discovery | Oct 15, 2014 | Sale | $15.00 | 2,004 | 30,060 | 109,152 | Oct 15, 2014, 04:52 PM |
Wennogle Lawrence P. | Vice President, Drug Discovery | Oct 08, 2014 | Sale | $15.00 | 4,745 | 71,175 | 112,756 | Oct 10, 2014, 05:05 PM |
Wennogle Lawrence P. | Vice President, Drug Discovery | Oct 06, 2014 | Sale | $15.00 | 636 | 9,540 | 117,501 | Oct 07, 2014, 04:30 PM |
Wennogle Lawrence P. | Vice President, Drug Discovery | Oct 03, 2014 | Sale | $15.00 | 15,863 | 237,945 | 118,137 | Oct 07, 2014, 04:30 PM |
Wennogle Lawrence P. | Vice President, Drug Discovery | Sep 15, 2014 | Sale | $15.00 | 5,000 | 75,000 | 134,000 | Sep 17, 2014, 05:12 PM |
Hineline Lawrence J. | VP of Finance CFO | Sep 08, 2014 | Option Exercise | $0.50 | 300 | 150 | 50,300 | Sep 10, 2014, 05:33 PM |
Hineline Lawrence J. | VP of Finance CFO | Sep 08, 2014 | Sale | $15.00 | 300 | 4,500 | 50,000 | Sep 10, 2014, 05:33 PM |
Wennogle Lawrence P. | Vice President, Drug Discovery | Jul 21, 2014 | Option Exercise | $0.50 | 37,500 | 18,750 | 139,000 | Jul 22, 2014, 05:31 PM |
ALAFI MOSHE | 10% Owner | Jun 19, 2014 | Sale | $6.35 | 15,742 | 100,006 | 0 | Jul 10, 2014, 04:56 PM |
Fienberg Allen A. | VP of Business Development | May 28, 2014 | Option Exercise | $0.50 | 37,500 | 18,750 | 275,000 | Jun 06, 2014, 05:23 PM |
Wennogle Lawrence P. | Vice President, Drug Discovery | May 27, 2014 | Sale | $15.00 | 5,000 | 75,000 | 101,500 | May 29, 2014, 06:30 PM |
Wennogle Lawrence P. | Vice President, Drug Discovery | May 22, 2014 | Sale | $15.00 | 6,000 | 89,983 | 110,806 | May 23, 2014, 07:46 PM |
RIGGS RORY B | Director | Feb 05, 2014 | Buy | $17.50 | 28,571 | 499,993 | 240,955 | Feb 05, 2014, 04:56 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Owner | Relationship | Date | Value($) |
RIGGS RORY B | Director | 03/20/2024 | 371,200 |
Mates Sharon | Chairman, President & CEO | 03/07/2024 | 2,707,277 |
Mates Sharon | Chairman, President & CEO | 03/11/2024 | 1,341,123 |
Hineline Lawrence J. | SVP of Finance, CFO | 03/10/2024 | 257,497 |
Hineline Lawrence J. | SVP of Finance, CFO | 03/11/2024 | 667,587 |
Hineline Lawrence J. | SVP of Finance, CFO | 03/07/2024 | 874,560 |
Halstead Michael | EVP and General Counsel | 03/11/2024 | 484,537 |
Halstead Michael | EVP and General Counsel | 03/07/2024 | 868,698 |
Neumann Mark | EVP, Chief Commercial Officer | 03/11/2024 | 481,931 |
Neumann Mark | EVP, Chief Commercial Officer | 03/07/2024 | 874,179 |
Durgam Suresh K. | EVP, Chief Medical Officer | 03/11/2024 | 243,482 |
Durgam Suresh K. | EVP, Chief Medical Officer | 03/07/2024 | 429,308 |
VAN NOSTRAND ROBERT L | Director | 02/27/2024 | 371,200 |
VAN NOSTRAND ROBERT L | Director | 02/27/2024 | 1,458,650 |
Halstead Michael | EVP and General Counsel | 02/26/2024 | 549,784 |
Hineline Lawrence J. | SVP of Finance, CFO | 02/26/2024 | 216,987 |
Hineline Lawrence J. | SVP of Finance, CFO | 02/26/2024 | 925,961 |
Mates Sharon | Chairman, President & CEO | 02/26/2024 | 1,576,464 |
Durgam Suresh K. | EVP, Chief Medical Officer | 02/26/2024 | 288,534 |
Neumann Mark | EVP, Chief Commercial Officer | 02/26/2024 | 554,491 |
MARCUS JOEL S | Director | 02/26/2024 | 1,798,678 |
MARCUS JOEL S | Director | 02/26/2024 | 1,808,253 |
Halstead Michael | EVP and General Counsel | 02/02/2024 | 787,719 |
Mates Sharon | Chairman, President & CEO | 02/02/2024 | 2,272,693 |
Neumann Mark | EVP, Chief Commercial Officer | 02/02/2024 | 796,367 |
Hineline Lawrence J. | SVP of Finance, CFO | 02/02/2024 | 745,037 |
Durgam Suresh K. | EVP, Chief Medical Officer | 02/02/2024 | 414,355 |
Mates Sharon | Chairman, President & CEO | 01/16/2024 | 1,270,587 |
Mates Sharon | Chairman, President & CEO | 01/18/2024 | 1,145,081 |
Mates Sharon | Chairman, President & CEO | 01/17/2024 | 810,696 |
Mates Sharon | Chairman, President & CEO | 01/16/2024 | 5,067,982 |
Mates Sharon | Chairman, President & CEO | 01/18/2024 | 4,427,849 |
Mates Sharon | Chairman, President & CEO | 01/17/2024 | 3,185,062 |
Halstead Michael | EVP and General Counsel | 01/11/2024 | 680,051 |
Halstead Michael | EVP and General Counsel | 01/11/2024 | 3,341,698 |
Durgam Suresh K. | EVP, Chief Medical Officer | 01/02/2024 | 1,237,543 |
Durgam Suresh K. | EVP, Chief Medical Officer | 01/02/2024 | 4,397,113 |
RIGGS RORY B | Director | 12/31/2023 | 17,977 |
VAN NOSTRAND ROBERT L | Director | 12/31/2023 | 5,443 |
Durgam Suresh K. | EVP, Chief Medical Officer | 12/13/2023 | 1,382,030 |
Halstead Michael | EVP and General Counsel | 11/13/2023 | 678,049 |
Halstead Michael | EVP and General Counsel | 11/13/2023 | 2,694,783 |
Neumann Mark | EVP, Chief Commercial Officer | 11/06/2023 | 640,491 |
Neumann Mark | EVP, Chief Commercial Officer | 11/06/2023 | 2,358,152 |
VAN NOSTRAND ROBERT L | Director | 09/30/2023 | 5,469 |
RIGGS RORY B | Director | 09/30/2023 | 17,971 |
Mates Sharon | Chairman, President & CEO | 09/19/2023 | 2,405,852 |
Mates Sharon | Chairman, President & CEO | 09/18/2023 | 2,988,213 |
Neumann Mark | EVP, Chief Commercial Officer | 08/07/2023 | 1,028,027 |
Neumann Mark | EVP, Chief Commercial Officer | 08/07/2023 | 3,251,087 |
Durgam Suresh K. | EVP, Chief Medical Officer | 07/17/2023 | 119,730 |
VAN NOSTRAND ROBERT L | Director | 06/30/2023 | 5,382 |
Hineline Lawrence J. | SVP of Finance CFO | 06/14/2023 | 3,462,317 |
Hineline Lawrence J. | SVP of Finance CFO | 06/14/2023 | 5,236,329 |
VAN NOSTRAND ROBERT L | Director | 04/17/2023 | 130,500 |
VAN NOSTRAND ROBERT L | Director | 04/17/2023 | 630,000 |
RIGGS RORY B | Director | 03/31/2023 | 16,949 |
Neumann Mark | EVP, Chief Commercial Officer | 03/28/2023 | 847,380 |
Durgam Suresh K. | EVP, Chief Medical Officer | 03/13/2023 | 330,794 |
Neumann Mark | EVP, Chief Commercial Officer | 03/13/2023 | 169,042 |
Neumann Mark | EVP, Chief Commercial Officer | 03/10/2023 | 370,557 |
Halstead Michael | EVP and General Counsel | 03/13/2023 | 330,007 |
Halstead Michael | EVP and General Counsel | 03/10/2023 | 720,086 |
Hineline Lawrence J. | SVP of Finance CFO | 03/13/2023 | 250,808 |
Hineline Lawrence J. | SVP of Finance CFO | 03/10/2023 | 674,417 |
Mates Sharon | Chairman, President & CEO | 03/13/2023 | 65,200 |
Mates Sharon | Chairman, President & CEO | 03/13/2023 | 925,275 |
Mates Sharon | Chairman, President & CEO | 03/10/2023 | 1,802,566 |
Neumann Mark | EVP, Chief Commercial Officer | 03/01/2023 | 362,122 |
Neumann Mark | EVP, Chief Commercial Officer | 02/24/2023 | 190,648 |
Durgam Suresh K. | SVP, Chief Medical Officer | 02/24/2023 | 372,689 |
Halstead Michael | EVP and General Counsel | 02/24/2023 | 371,819 |
Hineline Lawrence J. | SVP of Finance CFO | 02/24/2023 | 350,609 |
Mates Sharon | Chairman, President & CEO | 02/24/2023 | 97,800 |
Mates Sharon | Chairman, President & CEO | 02/24/2023 | 1,062,408 |
Neumann Mark | EVP, Chief Commercial Officer | 02/21/2023 | 183,246 |
Durgam Suresh K. | SVP, Chief Medical Officer | 02/21/2023 | 391,304 |
Halstead Michael | EVP and General Counsel | 02/21/2023 | 521,699 |
Hineline Lawrence J. | SVP of Finance CFO | 02/17/2023 | 687,013 |
Hineline Lawrence J. | SVP of Finance CFO | 02/21/2023 | 488,891 |
Hineline Lawrence J. | SVP of Finance CFO | 02/17/2023 | 2,689,464 |
Mates Sharon | Chairman, President & CEO | 02/21/2023 | 1,304,000 |
VAN NOSTRAND ROBERT L | Director | 12/30/2022 | 5,133 |
RIGGS RORY B | Director | 12/30/2022 | 16,987 |
MARCUS JOEL S | Director | 12/19/2022 | 254,100 |
Mates Sharon | Chairman, President & CEO | 12/13/2022 | 1,819,565 |
Halstead Michael | EVP and General Counsel | 12/01/2022 | 773,500 |
Halstead Michael | EVP and General Counsel | 12/01/2022 | 2,686,514 |
MARCUS JOEL S | Director | 11/07/2022 | 523,023 |
VAN NOSTRAND ROBERT L | Director | 09/30/2022 | 5,118 |
RIGGS RORY B | Director | 09/30/2022 | 16,983 |
Hineline Lawrence J. | SVP of Finance CFO | 09/21/2022 | 1,008,087 |
Hineline Lawrence J. | SVP of Finance CFO | 09/21/2022 | 2,973,406 |
VAN NOSTRAND ROBERT L | Director | 08/11/2022 | 379,500 |
VAN NOSTRAND ROBERT L | Director | 08/11/2022 | 1,713,975 |
MARCUS JOEL S | Director | 08/11/2022 | 592,200 |
RIGGS RORY B | Director | 06/30/2022 | 16,496 |
MARCUS JOEL S | Director | 05/12/2022 | 550,000 |
Neumann Mark | EVP, Chief Commercial Officer | 04/08/2022 | 1,099,210 |
Neumann Mark | EVP, Chief Commercial Officer | 04/08/2022 | 5,558,051 |
VAN NOSTRAND ROBERT L | Director | 03/31/2022 | 7,710 |
RIGGS RORY B | Director | 03/31/2022 | 15,726 |
RIGGS RORY B | Director | 03/18/2022 | 1,262,505 |
RIGGS RORY B | Director | 03/17/2022 | 8,536,646 |
RIGGS RORY B | Director | 03/16/2022 | 3,824,827 |
Mates Sharon | Chairman, President & CEO | 03/09/2022 | 110,547 |
MARCUS JOEL S | Director | 03/08/2022 | 790,150 |
MARCUS JOEL S | Director | 03/07/2022 | 272,600 |
Durgam Suresh K. | Chief Medical Officer | 03/02/2022 | 238,005 |
Durgam Suresh K. | Chief Medical Officer | 03/04/2022 | 214,307 |
Durgam Suresh K. | Chief Medical Officer | 02/24/2022 | 211,468 |
Neumann Mark | EVP, Chief Commercial Officer | 02/24/2022 | 412,810 |
Halstead Michael | EVP and General Counsel | 02/24/2022 | 410,933 |
Hineline Lawrence J. | SVP of Finance CFO | 02/24/2022 | 387,349 |
Mates Sharon | Chairman, President & CEO | 02/24/2022 | 1,174,074 |
Durgam Suresh K. | Chief Medical Officer | 02/22/2022 | 230,958 |
Neumann Mark | EVP, Chief Commercial Officer | 02/22/2022 | 615,827 |
Halstead Michael | EVP and General Counsel | 02/22/2022 | 617,100 |
Hineline Lawrence J. | SVP of Finance CFO | 02/22/2022 | 578,506 |
Mates Sharon | Chairman, President & CEO | 02/22/2022 | 1,542,413 |
Durgam Suresh K. | Chief Medical Officer | 01/18/2022 | 261,553 |
Durgam Suresh K. | Chief Medical Officer | 01/10/2022 | 280,020 |
Neumann Mark | EVP, Chief Commercial Officer | 01/10/2022 | 854,255 |
Halstead Michael | EVP and General Counsel | 01/10/2022 | 800,774 |
Hineline Lawrence J. | SVP of Finance CFO | 01/10/2022 | 800,420 |
Mates Sharon | Chairman, President & CEO | 01/10/2022 | 1,708,429 |
VAN NOSTRAND ROBERT L | Director | 12/31/2021 | 7,746 |
RIGGS RORY B | Director | 12/31/2021 | 15,702 |
Halstead Michael | EVP and General Counsel | 12/21/2021 | 2,897,494 |
Halstead Michael | EVP and General Counsel | 12/21/2021 | 8,412,278 |
Hineline Lawrence J. | SVP of Finance CFO | 12/21/2021 | 2,941,951 |
Hineline Lawrence J. | SVP of Finance CFO | 12/21/2021 | 8,328,664 |
Neumann Mark | EVP, Chief Commercial Officer | 10/18/2021 | 549,551 |
Mates Sharon | Chairman, President & CEO | 10/15/2021 | 3,053 |
Mates Sharon | Chairman, President & CEO | 10/15/2021 | 1,615,680 |
Mates Sharon | Chairman, President & CEO | 10/14/2021 | 56,640 |
Mates Sharon | Chairman, President & CEO | 10/18/2021 | 327,680 |
LERNER RICHARD A | Director | 09/30/2021 | 14,987 |
RIGGS RORY B | Director | 09/30/2021 | 15,732 |
VAN NOSTRAND ROBERT L | Director | 09/30/2021 | 8,015 |
Mates Sharon | Chairman, President & CEO | 08/23/2021 | 28,400 |
VAN NOSTRAND ROBERT L | Director | 06/30/2021 | 7,062 |
RIGGS RORY B | Director | 06/30/2021 | 15,716 |
LERNER RICHARD A | Director | 06/30/2021 | 14,981 |
Alafi Christopher D | Director | 05/24/2021 | 1,075,490 |
Alafi Christopher D | Director | 05/21/2021 | 44,000 |
LERNER RICHARD A | Director | 03/31/2021 | 14,997 |
MARCUS JOEL S | Director | 03/02/2021 | 531,600 |
MARCUS JOEL S | Director | 03/02/2021 | 532,683 |
Durgam Suresh K. | Chief Medical Officer | 02/19/2021 | 107,310 |
Neumann Mark | EVP, Chief Commercial Officer | 02/19/2021 | 203,308 |
Hineline Lawrence J. | SVP of Finance CFO | 02/19/2021 | 409,625 |
Halstead Michael | EVP and General Counsel | 02/19/2021 | 437,133 |
Mates Sharon | Chairman, President & CEO | 02/19/2021 | 1,092,436 |
Durgam Suresh K. | Chief Medical Officer | 01/11/2021 | 140,259 |
Neumann Mark | EVP, Chief Commercial Officer | 01/11/2021 | 310,082 |
Hineline Lawrence J. | SVP of Finance CFO | 01/11/2021 | 628,769 |
Halstead Michael | EVP and General Counsel | 01/11/2021 | 628,978 |
Mates Sharon | Chairman, President & CEO | 01/11/2021 | 1,341,260 |
Hineline Lawrence J. | SVP of Finance CFO | 01/04/2021 | 495,008 |
Halstead Michael | EVP and General Counsel | 01/04/2021 | 505,834 |
Mates Sharon | Chairman, President & CEO | 01/04/2021 | 1,513,271 |
LERNER RICHARD A | Director | 12/31/2020 | 14,978 |
VAN NOSTRAND ROBERT L | Director | 12/31/2020 | 7,060 |
RIGGS RORY B | Director | 12/31/2020 | 15,741 |
Alafi Christopher D | Director | 12/31/2020 | 15,741 |
Mates Sharon | Chairman, President & CEO | 12/18/2020 | 93,160 |
Halstead Michael | EVP and General Counsel | 11/17/2020 | 1,039,500 |
Halstead Michael | EVP and General Counsel | 11/17/2020 | 2,193,446 |
Hineline Lawrence J. | SVP of Finance CFO | 11/11/2020 | 61,000 |
Hineline Lawrence J. | SVP of Finance CFO | 11/11/2020 | 712,344 |
Mates Sharon | Chairman, President & CEO | 11/10/2020 | 1,317,101 |
Mates Sharon | Chairman, President & CEO | 11/04/2020 | 1,250,000 |
Neumann Mark | EVP, Chief Commercial Officer | 10/16/2020 | 182,026 |
VAN NOSTRAND ROBERT L | Director | 09/30/2020 | 7,082 |
RIGGS RORY B | Director | 09/30/2020 | 15,730 |
LERNER RICHARD A | Director | 09/30/2020 | 14,985 |
Alafi Christopher D | Director | 09/30/2020 | 15,730 |
Alafi Christopher D | Director | 09/14/2020 | 1,465,200 |
Hineline Lawrence J. | SVP of Finance CFO | 09/09/2020 | 343,494 |
Hineline Lawrence J. | SVP of Finance CFO | 09/09/2020 | 1,307,351 |
Alafi Christopher D | Director | 09/11/2020 | 589,680 |
VAN NOSTRAND ROBERT L | Director | 06/30/2020 | 7,059 |
LERNER RICHARD A | Director | 06/30/2020 | 14,991 |
RIGGS RORY B | Director | 06/30/2020 | 15,736 |
Alafi Christopher D | Director | 06/30/2020 | 15,736 |
MARCUS JOEL S | Director | 05/14/2020 | 192,424 |
MARCUS JOEL S | Director | 05/11/2020 | 997,500 |
MARCUS JOEL S | Director | 05/13/2020 | 150,537 |
LERNER RICHARD A | Director | 05/11/2020 | 68,500 |
LERNER RICHARD A | Director | 05/11/2020 | 71,750 |
Alafi Christopher D | Director | 03/31/2020 | 15,739 |
LERNER RICHARD A | Director | 03/31/2020 | 14,986 |
VAN NOSTRAND ROBERT L | Director | 03/31/2020 | 7,070 |
RIGGS RORY B | Director | 03/31/2020 | 15,739 |
Halstead Michael | EVP and General Counsel | 01/24/2020 | 89,930 |
Hineline Lawrence J. | SVP of Finance CFO | 01/24/2020 | 89,930 |
Mates Sharon | Chairman, President & CEO | 01/24/2020 | 220,116 |
LERNER RICHARD A | Director | 12/31/2019 | 13,724 |
Satlin Andrew | EVP and Chief Medical Officer | 01/09/2020 | 302,750 |
Neumann Mark | EVP, Chief Commercial Officer | 01/08/2020 | 162,175 |
Mates Sharon | Chairman, President & CEO | 01/09/2020 | 1,095,973 |
Halstead Michael | EVP and General Counsel | 01/09/2020 | 513,730 |
Hineline Lawrence J. | SVP of Finance CFO | 01/09/2020 | 513,730 |
Mates Sharon | Chairman, President & CEO | 01/08/2020 | 164,400 |
Mates Sharon | Chairman, President & CEO | 01/06/2020 | 1,380,880 |
Halstead Michael | EVP and General Counsel | 01/06/2020 | 651,007 |
Hineline Lawrence J. | SVP of Finance CFO | 01/06/2020 | 650,003 |
Halstead Michael | EVP and General Counsel | 01/02/2020 | 253,214 |
Hineline Lawrence J. | SVP of Finance CFO | 01/02/2020 | 253,165 |
Mates Sharon | Chairman, President & CEO | 12/31/2019 | 16,440 |
Mates Sharon | Chairman, President & CEO | 01/02/2020 | 567,230 |
VAN NOSTRAND ROBERT L | Director | 12/31/2019 | 5,833 |
RIGGS RORY B | Director | 12/31/2019 | 14,479 |
Alafi Christopher D | Director | 12/31/2019 | 14,479 |
Hineline Lawrence J. | SVP of Finance CFO | 12/23/2019 | 26,304 |
Hineline Lawrence J. | SVP of Finance CFO | 12/23/2019 | 383,316 |
Neumann Mark | EVP, Chief Commercial Officer | 10/16/2019 | 55,886 |
RIGGS RORY B | Director | 09/30/2019 | 14,499 |
LERNER RICHARD A | Director | 09/30/2019 | 13,745 |
VAN NOSTRAND ROBERT L | Director | 09/30/2019 | 5,827 |
Alafi Christopher D | Director | 09/30/2019 | 14,499 |
Alafi Christopher D | Director | 09/10/2019 | 4,974,678 |
Alafi Christopher D | Director | 08/30/2019 | 1,065,212 |
VAN NOSTRAND ROBERT L | Director | 06/28/2019 | 5,828 |
LERNER RICHARD A | Director | 06/28/2019 | 13,746 |
RIGGS RORY B | Director | 06/28/2019 | 14,499 |
Alafi Christopher D | Director | 06/28/2019 | 14,499 |
Alafi Christopher D | Director | 11/22/2017 | 155,500 |
Alafi Christopher D | Director | 06/12/2019 | 1,993,793 |
MARCUS JOEL S | Director | 05/29/2019 | 249,000 |
Alafi Christopher D | Director | 05/14/2019 | 1,256,350 |
Alafi Christopher D | Director | 03/31/2019 | 14,494 |
VAN NOSTRAND ROBERT L | Director | 03/31/2019 | 5,822 |
RIGGS RORY B | Director | 03/31/2019 | 14,494 |
LERNER RICHARD A | Director | 03/31/2019 | 13,739 |
Hineline Lawrence J. | SVP of Finance CFO | 02/27/2019 | 28,496 |
Hineline Lawrence J. | SVP of Finance CFO | 02/27/2019 | 15,000 |
Mates Sharon | Chairman, President & CEO | 01/07/2019 | 82,088 |
Mates Sharon | Chairman, President & CEO | 01/04/2019 | 522,222 |
Halstead Michael | EVP and General Counsel | 01/07/2019 | 38,601 |
Halstead Michael | EVP and General Counsel | 01/04/2019 | 245,817 |
Hineline Lawrence J. | SVP of Finance CFO | 01/07/2019 | 38,601 |
Hineline Lawrence J. | SVP of Finance CFO | 01/04/2019 | 245,782 |
Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | 01/04/2019 | 109,704 |
Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | 01/07/2019 | 7,276 |
Davis Robert E | SVP, Chief Scientific Officer | 01/04/2019 | 109,630 |
Mates Sharon | Chairman, President & CEO | 01/02/2019 | 193,831 |
Halstead Michael | EVP and General Counsel | 01/02/2019 | 86,580 |
Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | 01/02/2019 | 53,657 |
Davis Robert E | SVP, Chief Scientific Officer | 01/02/2019 | 53,706 |
Hineline Lawrence J. | SVP of Finance CFO | 01/02/2019 | 86,580 |
VAN NOSTRAND ROBERT L | Director | 12/31/2018 | 5,832 |
RIGGS RORY B | Director | 12/31/2018 | 14,499 |
LERNER RICHARD A | Director | 12/31/2018 | 13,748 |
Alafi Christopher D | Director | 12/31/2018 | 14,499 |
Mates Sharon | Chairman, President & CEO | 12/10/2018 | 75,000 |
Davis Robert E | SVP, Chief Scientific Officer | 12/06/2018 | 12,163 |
MARCUS JOEL S | Director | 11/12/2018 | 125,580 |
MARCUS JOEL S | Director | 11/09/2018 | 456,000 |
LERNER RICHARD A | Director | 10/22/2018 | 18,750 |
LERNER RICHARD A | Director | 09/30/2018 | 13,736 |
RIGGS RORY B | Director | 09/30/2018 | 14,496 |
VAN NOSTRAND ROBERT L | Director | 09/30/2018 | 5,816 |
Alafi Christopher D | Director | 09/30/2018 | 14,496 |
LERNER RICHARD A | Director | 06/29/2018 | 13,747 |
Alafi Christopher D | Director | 06/29/2018 | 14,489 |
VAN NOSTRAND ROBERT L | Director | 06/29/2018 | 4,983 |
RIGGS RORY B | Director | 06/29/2018 | 14,489 |
VAN NOSTRAND ROBERT L | Director | 03/30/2018 | 4,989 |
RIGGS RORY B | Director | 03/30/2018 | 14,482 |
LERNER RICHARD A | Director | 03/30/2018 | 13,746 |
Alafi Christopher D | Director | 03/30/2018 | 14,482 |
Hineline Lawrence J. | VP of Finance CFO | 02/16/2018 | 326,543 |
Hineline Lawrence J. | VP of Finance CFO | 02/15/2018 | 668,621 |
Halstead Michael | SVP and General Counsel | 01/22/2018 | 459,765 |
Vanover Kimberly E. | SVP, Clinical Development | 01/08/2018 | 13,479 |
Mates Sharon | Chairman, President & CEO | 01/08/2018 | 115,438 |
Mates Sharon | Chairman, President & CEO | 01/05/2018 | 192,270 |
Vanover Kimberly E. | SVP, Clinical Development | 01/05/2018 | 20,583 |
Davis Robert E | SVP, Chief Scientific Officer | 01/04/2018 | 17,394 |
Hineline Lawrence J. | VP of Finance CFO | 01/04/2018 | 50,019 |
Hineline Lawrence J. | VP of Finance CFO | 01/05/2018 | 32,706 |
Halstead Michael | SVP and General Counsel | 01/05/2018 | 27,284 |
Halstead Michael | SVP and General Counsel | 01/04/2018 | 41,895 |
VAN NOSTRAND ROBERT L | Director | 12/29/2017 | 4,996 |
RIGGS RORY B | Director | 12/29/2017 | 14,494 |
LERNER RICHARD A | Director | 12/29/2017 | 13,742 |
Alafi Christopher D | Director | 12/29/2017 | 14,494 |
VAN NOSTRAND ROBERT L | Director | 12/29/2017 | 4,996 |
LERNER RICHARD A | Director | 12/29/2017 | 13,742 |
RIGGS RORY B | Director | 12/29/2017 | 14,494 |
Alafi Christopher D | Director | 12/29/2017 | 14,494 |
LERNER RICHARD A | Director | 12/11/2017 | 18,750 |
LERNER RICHARD A | Director | 12/11/2017 | 105,630 |
Davis Robert E | SVP, Chief Scientific Officer | 12/05/2017 | 9,750 |
Alafi Christopher D | Director | 11/22/2017 | 155,500 |
Mates Sharon | Chairman, President & CEO | 10/30/2017 | 28,125 |
Mates Sharon | Chairman, President & CEO | 10/30/2017 | 295,313 |
ALAFI MOSHE | 10% Owner | 10/02/2017 | 4,000,008 |
Alafi Christopher D | Director | 10/02/2017 | 4,000,008 |
ALAFI CAPITAL CO LLC | 10% Owner | 10/02/2017 | 4,000,008 |
MARCUS JOEL S | Director | 01/26/2017 | 247,450 |
Vanover Kimberly E. | SVP, Clinical Development | 01/05/2017 | 13,272 |
Mates Sharon | Chairman, President & CEO | 01/05/2017 | 67,541 |
Hineline Lawrence J. | VP of Finance CFO | 01/05/2017 | 31,800 |
Halstead Michael | SVP and General Counsel | 01/05/2017 | 26,497 |
Vanover Kimberly E. | SVP, Clinical Development | 12/15/2016 | 27,425 |
Vanover Kimberly E. | SVP, Clinical Development | 12/15/2016 | 142,773 |
ALAFI MOSHE | 10% Owner | 12/07/2016 | 336,038 |
ALAFI MOSHE | 10% Owner | 12/06/2016 | 721,445 |
Alafi Christopher D | Director | 12/07/2016 | 336,038 |
Alafi Christopher D | Director | 12/06/2016 | 721,445 |
ALAFI CAPITAL CO LLC | 10% Owner | 12/07/2016 | 336,038 |
ALAFI CAPITAL CO LLC | 10% Owner | 12/06/2016 | 721,445 |
ALAFI MOSHE | 10% Owner | 11/14/2016 | 492,969 |
ALAFI CAPITAL CO LLC | 10% Owner | 11/14/2016 | 492,969 |
Alafi Christopher D | Director | 11/14/2016 | 492,969 |
RIGGS RORY B | Director | 02/05/2014 | 249,988 |
RIGGS RORY B | Director | 02/05/2014 | 250,005 |
Alafi Christopher D | Director | 02/29/2016 | 2,970,300 |
LERNER RICHARD A | Director | 02/18/2016 | 13,600 |
VAN NOSTRAND ROBERT L | Director | 12/31/2015 | 3,712 |
RIGGS RORY B | Director | 12/31/2015 | 10,597 |
MARCUS JOEL S | Director | 12/31/2015 | 10,704 |
Alafi Christopher D | Director | 12/31/2015 | 10,489 |
LERNER RICHARD A | Director | 12/31/2015 | 10,113 |
Mates Sharon | Chairman, President & CEO | 12/11/2015 | 77,125 |
Mates Sharon | Chairman, President & CEO | 12/11/2015 | 2,774,441 |
Hineline Lawrence J. | VP of Finance CFO | 12/15/2015 | 50,750 |
Hineline Lawrence J. | VP of Finance CFO | 12/14/2015 | 4,500 |
Hineline Lawrence J. | VP of Finance CFO | 11/24/2015 | 3,000 |
Hineline Lawrence J. | VP of Finance CFO | 12/15/2015 | 1,169,226 |
Hineline Lawrence J. | VP of Finance CFO | 12/14/2015 | 1,146,140 |
MARCUS JOEL S | Director | 12/08/2015 | 1,243,960 |
MARCUS JOEL S | Director | 12/07/2015 | 2,126,628 |
MARCUS JOEL S | Director | 12/04/2015 | 1,678,800 |
Hineline Lawrence J. | VP of Finance CFO | 11/24/2015 | 275,000 |
Fienberg Allen A. | VP of Business Development | 09/09/2015 | 17,000 |
Fienberg Allen A. | VP of Business Development | 08/21/2015 | 6,060 |
Fienberg Allen A. | VP of Business Development | 08/19/2015 | 303,000 |
Wennogle Lawrence P. | Vice President, Drug Discovery | 06/08/2015 | 671,000 |
Wennogle Lawrence P. | Vice President, Drug Discovery | 05/19/2015 | 58,250 |
Fienberg Allen A. | VP of Business Development | 03/31/2015 | 7,500 |
MARCUS JOEL S | Director | 03/31/2015 | 18,400 |
Alafi Christopher D | Director | 03/11/2015 | 15,000,000 |
Fienberg Allen A. | VP of Business Development | 01/14/2015 | 95,000 |
Hineline Lawrence J. | VP of Finance CFO | 12/09/2014 | 190,558 |
Hineline Lawrence J. | VP of Finance CFO | 12/08/2014 | 185,418 |
Hineline Lawrence J. | VP of Finance CFO | 12/02/2014 | 18,600 |
Alafi Christopher D | Director | 12/01/2014 | 20,975 |
ALAFI MOSHE | 10% Owner | 12/01/2014 | 20,975 |
ALAFI CAPITAL CO LLC | 10% Owner | 12/01/2014 | 20,975 |
ALAFI CAPITAL CO LLC | 10% Owner | 11/28/2014 | 516,250 |
ALAFI MOSHE | 10% Owner | 11/28/2014 | 516,250 |
Alafi Christopher D | Director | 11/28/2014 | 516,250 |
Mates Sharon | Chairman, President & CEO | 11/25/2014 | 25,000 |
Mates Sharon | Chairman, President & CEO | 11/28/2014 | 516,250 |
Alafi Christopher D | Director | 11/19/2014 | 14,735 |
ALAFI MOSHE | 10% Owner | 11/19/2014 | 14,735 |
ALAFI CAPITAL CO LLC | 10% Owner | 11/19/2014 | 14,735 |
Alafi Christopher D | Director | 11/18/2014 | 50,246 |
Alafi Christopher D | Director | 11/14/2014 | 2,004 |
ALAFI MOSHE | 10% Owner | 11/18/2014 | 50,246 |
ALAFI MOSHE | 10% Owner | 11/14/2014 | 2,004 |
ALAFI CAPITAL CO LLC | 10% Owner | 11/18/2014 | 50,246 |
ALAFI CAPITAL CO LLC | 10% Owner | 11/14/2014 | 2,004 |
Alafi Christopher D | Director | 11/13/2014 | 33,264 |
Alafi Christopher D | Director | 11/12/2014 | 76,150 |
Alafi Christopher D | Director | 11/11/2014 | 77,750 |
ALAFI MOSHE | 10% Owner | 11/11/2014 | 77,750 |
ALAFI MOSHE | 10% Owner | 11/13/2014 | 33,264 |
ALAFI MOSHE | 10% Owner | 11/12/2014 | 76,150 |
ALAFI CAPITAL CO LLC | 10% Owner | 11/13/2014 | 33,264 |
ALAFI CAPITAL CO LLC | 10% Owner | 11/12/2014 | 76,150 |
ALAFI CAPITAL CO LLC | 10% Owner | 11/11/2014 | 77,750 |
Halstead Michael | SVP and General Counsel | 11/06/2014 | 201,110 |
Halstead Michael | SVP and General Counsel | 11/05/2014 | 106,470 |
Wennogle Lawrence P. | Vice President, Drug Discovery | 10/16/2014 | 77,280 |
Wennogle Lawrence P. | Vice President, Drug Discovery | 10/13/2014 | 24,000 |
Wennogle Lawrence P. | Vice President, Drug Discovery | 10/15/2014 | 30,060 |
Wennogle Lawrence P. | Vice President, Drug Discovery | 10/08/2014 | 71,175 |
Wennogle Lawrence P. | Vice President, Drug Discovery | 10/06/2014 | 9,540 |
Wennogle Lawrence P. | Vice President, Drug Discovery | 10/03/2014 | 237,945 |
Wennogle Lawrence P. | Vice President, Drug Discovery | 09/15/2014 | 75,000 |
Hineline Lawrence J. | VP of Finance CFO | 09/08/2014 | 150 |
Hineline Lawrence J. | VP of Finance CFO | 09/08/2014 | 4,500 |
Wennogle Lawrence P. | Vice President, Drug Discovery | 07/21/2014 | 18,750 |
ALAFI MOSHE | 10% Owner | 06/19/2014 | 100,006 |
Fienberg Allen A. | VP of Business Development | 05/28/2014 | 18,750 |
Wennogle Lawrence P. | Vice President, Drug Discovery | 05/27/2014 | 75,000 |
Wennogle Lawrence P. | Vice President, Drug Discovery | 05/22/2014 | 89,983 |
RIGGS RORY B | Director | 02/05/2014 | 499,993 |
Load More Insider Transactions
FUNDS WITH A POSITION IN INTRA-CELLULAR THERAPIES INC
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
BLACKROCK INC. | 8,193,544 | 0.01% | 9.03% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 2,001,791 | 0.02% | 4.75% | Other |
HOLOCENE ADVISORS, LP | 1,261,857 | 0.35% | -11.91% | Growth At A Reasonable Price |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,165,948 | 3.78% | -14.88% | Growth At A Reasonable Price |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 275,000 | 0.04% | -68.93% | Other |
D. E. SHAW & CO., INC. | 511,550 | 0.03% | -31% | Other |
BALYASNY ASSET MANAGEMENT L.P. | 309,993 | 0.04% | New | Event Driven |
RENAISSANCE TECHNOLOGIES LLC | 152,400 | 0.02% | -42.27% | Other |
TIG ADVISORS, LLC | 129,300 (Call) | 1.16% | New | Event Driven |
TUDOR INVESTMENT CORP ET AL | 51,555 | 0.03% | 42.11% | Event Driven, Other |
BALYASNY ASSET MANAGEMENT L.P. | 50,000 (Call) | 0.00672% | New | Event Driven |
AQR CAPITAL MANAGEMENT LLC | 38,713 | 0.00522% | 29.31% | Other |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,910 | 0.00385% | New | Other |
CHANGE IN SHARES OUTSTANDING FOR INTRA-CELLULAR THERAPIES INC
STOCK BUYBACKS FOR INTRA-CELLULAR THERAPIES INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.15%
1Q
06/30/2023
0.36%
2Q
03/31/2023
1.21%
3Q
12/31/2022
1.62%
4Q
09/30/2022
1.88%
5Q
06/30/2022
2.13%
6Q
03/31/2022
3.98%
7Q
12/31/2021
18.18%
8Q
09/30/2021
18.36%
9Q
06/30/2021
18.54%
10Q
03/31/2021
18.96%
11Q
12/31/2020
19.81%
12Q
09/30/2020
38.49%
13Q
06/30/2020
44.95%
14Q
03/31/2020
47.90%
15Q
12/31/2019
74.19%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR INTRA-CELLULAR THERAPIES INC
LOADING...